QIAGEN N.V. (Nasdaq: QGEN) today announced it has entered into a master collaboration agreement with the Swiss pharmaceutical company Novartis AG (NYSE: NVS) to enable the development and commercialization of companion diagnostics to be paired with existing Novartis pharmaceutical products as well as compounds in its development pipeline.
The non-exclusive agreement with Novartis creates a framework for collaborations that would include developing QIAGEN companion diagnostics to guide treatment decisions for Novartis pharmaceutical products. The scope of the collaboration can cover all QIAGEN platforms, indications or biomarkers. Financial terms of the agreement were not disclosed.
LabCentral and Roche announced an agreement in which Roche would provide technology and financial support to LabCentral, a first-of-its-kind shared laboratory space designed as a launchpad for high-potential life-sciences and biotech startups.
WellDoc®, a leading digital health care behavioral science and technology company has launched a multi-stage collaboration effort with Samsung Electronics Co. Ltd, to improve the lives of those living with type 2 diabetes and explore next generation diabetes devices and product offerings.
View gallery . The parties share a vision for leveraging technology to empower patient self-management and provider clinical decision-making. They each have commercialized unique and powerful health care platforms that when combined, can deliver unparalleled support to patients with diabetes.
Startup Maryland (http://www.startupmd.org) today announced the Great two top Finalists from the 2014 Pitch Across Maryland celebration.
After qualifying and posting more than 150 video pitches from Maryland entrepreneurs that were captured during the three-week Pitch Across Maryland tour | celebration, Startup Maryland is proud to announce Vheda Health (Howard County/MCE) and BrinkBit (uBalt, ETC, EAGB, GBC) as Winner and Runner-up, respectively.
Montgomery County Executive Ike Leggett is hoping to broaden Montgomery County’s reach in biotech and other high-tech areas as he leads a delegation of two dozen County businessmen and businesswomen to India this month.
Among those joining Leggett are Maryland State Delegate Aruna Miller, Montgomery County Councilmember Nancy Floreen, Montgomery College President Dr. DeRionne P. Pollard, Global LifeSci Development Corporation executive vice president Jonathan Genn, President & CEO of the India-US World Affairs Institute Vinod Jain, and former White House communications director Ann Lewis.
If you’re a foreign entrepreneur looking to break into the U.S. market, the State of Maryland wants to help.
On the third floor of a nondescript office building perched on a busy commercial strip in College Park, Maryland, foreign-owned startups can get a boost at the Maryland International Incubator, a first-of-its-kind incubator focused exclusively on foreign companies settling in the United States.
A Johns Hopkins astrophysicist will share in a $3 million prize for his discovery that the universe is expanding rapidly, contrary to earlier belief.
Adam Riess, who previously won a Nobel Prize for his work, has been awarded the Breakthrough Prize in Fundamental Physics. Riess shares the award with research partner Brian P. Schmidt of the Australian National University and University of California, Berkeley astrophysicist Saul Perlmutter.
Swiss drugmaker Roche said Friday that the Food and Drug Administration approved its drug Avastin as a treatment for ovarian cancer.
Roche said the FDA approved Avastin in combination with chemotherapy as a treatment for recurrent cases of cancer that are resistant to platinum-based chemotherapy.
Join us Nov. 20 for the 15th annual Bioscience Day at the University of Maryland, where we will explore “Scientific Advances in Treating Trauma and Disease.”
Join BioBuzz and our sponsor CRB for another great BioBuzz networking event on November 19th from 5:00 – 7:30 p.m. @ American Tap Room in Rockville, MD. This location is a short walk from the Metro located in the Rockville Town Center.
The MCCC Business Awards Dinner Committee and Chair of the Board Lisa Cines, CPA of Dixon Hughes Goodman LLP invite you to join in the celebration of those who make our economy and community thrive. This annual sold-out event attracts 700+ guests including award winners, sponsors, business leaders, elected and government officials and the media. Join us for a great evening of Meaningful Connections, Commerce and Celebration.
Seniors in the University of Maryland’s Fischell Department of BioEngineering (BioE) design and build devices designed to improve patient outcomes and health care while lowering costs. BioE teams are typically matched with a pair of advisors including a BioE faculty member and a physician from the University of Maryland Medical Center. The teams are assisted by University engineers for fabrication and by business advisors for entrepreneurship. This year, there are 91 students comprising 18 teams of innovators full of fearless ideas.
Eighth grader Lily DeBell won the 2014 NFTE National Youth Entrepreneurship Challenge, presented by the MasterCard Center for Inclusive Growth.
DeBell, who is still in middle school, finished ahead of 40 other student entrepreneurs from across the county – almost all of them were either High School or college age students.
In a breakthrough in the design of batteries, a research funded by the US Department of Energy has produced a remarkable new prototype battery that just needs 12 minutes to get fully recharged compared to the hours the conventional cells take up to get replenished.
Researchers at the University of Maryland who were involved in this research stated that their new invention can work towards the long sought-for miniaturization of energy storage components. This breakthrough can certainly help towards allowing electric cars to give petrol-powered vehicles a run for their money.
Notice of Intent to Publish a Funding Opportunity Announcement for Science of Behavior Change: Assay Development and Validation for Self-Regulation Targets (UH2/UH3)
Notice of Intent to Publish a Funding Opportunity Announcement for Science of Behavior Change: Assay Development and Validation for Stress Reactivity and Stress Resilience Targets (UH2/UH3)
Notice of Intent to Publish a Funding Opportunity Announcement for Science of Behavior Change: Assay Development and Validation for Interpersonal and Social Processes Targets (UH2/UH3)
Application Receipt Date(s): February 18, 2015, September 18, 2015 (resubmissions only), February 18, 2016, September 19, 2016 (resubmissions only); February 18, 2017, September 18, 2017 (resubmissions only) by 5:00 PM local time of applicant organization.
Program Announcements:
Administrative Supplements for Research on Sex/Gender Differences (Admin Supp)
The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:
Notices:
Notice Announcing Frequently Asked Questions (FAQs) for RFA-RM-14-016 “Model Organisms Screening Center for the Undiagnosed Diseases Network (UDN) (U54)
Application Receipt Date(s): February 20, 2015 (Phase I or Fast-Track); February 20, 2016 (Phase I; Phase II; or Fast-Track); February 20, 2017 (Phase II only)
NHLBI Bench to Bassinet Program Administrative Coordinating Center (U01)
Application Receipt/Submission Date(s): Multiple dates, see announcement.
Please note that most links to RFAs, PAs, and Guide Notices will take you to the NIH Web site. RFPs will take you to FedBizOpps. Links to RFPs will not work past their proposal receipt date. Archived versions of RFPs posted on FedBizOpps can be found on the FedBizOpps site using the FedBizOpps search function. Under “Document to Search,” select Archived Documents.
The 1776 incubator, which is interested in helping startups break down geographic barriers and collaborating with other incubators and accelerators has announced a partnership with a major physician association — the American College of Cardiology, according to a company statement. The cardiology association will play a role not only in the incubator’s Challenge Cup, but also longer term.
The United States has over 5,700 hospitals, and most of them are central to their communities for an obvious reason: They help people get healthier. When I look at these hospitals, I see an untapped resource, a way they could provide greater value to their communities and the country.
Intellectual assets — the ideas and know-how in the heads of clinicians — are vital, intangible resources for most hospitals. They’re equivalent to the research assets at universities. In addition to knowledge and know-how, clinicians working in hospitals are creating ideas for new health care technologies (apps, processes, devices, therapies, drugs) and cost-effective care models, often as part of their response to the value-based care principles of health care reform.
Americans include two health-related issues among the 10 most important problems facing the U.S., according to a recent Gallup survey. Healthcare in general ranked fourth on the list, with Ebola coming in at no. 8. But is Ebola really among the biggest health problems for Americans? Not when we look at the chances of actually being infected.
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
Thomas Kucharski (IEDC) – Ethan Byler (BHI) – William C. Sproull (IEDC)
BioHealth Innovation, Inc. (BHI) was selected as an International Economic Development Council (IEDC) Excellence in Economic Development Silver Award recipient. BHI is receiving the award in the Public-Private Partnerships category for its work to assemblethe partnership that sponsored DreamIt Health IT Baltimore accelerator program. The award, which recognizes outstanding and innovative development projects that have significantly enhanced the economic revitalization of distressed communities, states, or regions, was formally presented to BHI on Monday, October 20, during the 2014 IEDC Annual Conference in Fort Worth, TX.
“BHI is honored to be acknowledged with this award for our work with DreamIt Health in support of the DreamIt Health Baltimore program in 2014,” said Richard Bendis, BHI President & CEO. “This reinforces the dedication to entrepreneurship and innovation in the biohealth arena that we are constantly striving for in Central Maryland.”
Tuesday said its global biologics research and development arm, MedImmune, has agreed to buy privately-held Definiens, which would strengthen MedImmune’s focus on the discovery of novel predictive biomarkers in immuno-oncology.
Definiens is into imaging and data analysis technology, known as Tissue Phenomics, which dramatically improves the identification of biomarkers in tumour tissue.
Considering that Emergent BioSolutions (NYSE: EBS ) has regular government contracts and other manufacturing contracts — so regular that it’s willing to give quarterly guidance, which many companies wouldn’t dream of — it was a little surprising to see by how much the biotech beat the guidance it gave three months earlier. Third-quarter revenue came in at $138 million, substantially higher than the guidance of $110 million to $125 million it gave three months ago.
But, as it turns out, this is just an accounting issue. In the third quarter, Emergent BioSolutions set up a collaboration with MorphoSys to develop its prostate cancer drug candidate ES414. Under the terms of the agreement, Emergent BioSolutions got a $20 million upfront payment — the biotech recognized $15.3 million of this in the third quarter. Back out the payment, and Emergent BioSolutions’ revenue falls within its previous guidance, fortunately at the upper-end.
Osiris has a history of developing treatments — like Prochymal, the first government-approved stem cell drug — and then selling them to other companies. Its product portfolio is thus diverse, and that is wise when it comes to Grafix, which competes with a number of other advanced wound care products.
Ryan Sysko needed someone to push WellDoc’s diabetes management app, BlueStar, into the market. It was time to turn to an outsider to make sure BlueStar successfully sold in Maryland and, eventually, nationwide. The FDA-approved smartphone app helps diabetes patients track blood glucose levels, medications, diet and exercise on a cellphone. It requires a prescription from a doctor.
To take on the task, Sysko, the Baltimore health care technology company’s CEO, called on Kevin P. McRaith. Former vice president of …
A year ago Robert Lord and Nick Culbertson were medical students with an idea for a company.
Now their startup Protenus Inc. is doing business with Johns Hopkins Hospital, figuring out how to use $770,000 in seed financing and hiring staff members to get their cyber security system in more hospitals.
Cartagenia announced today that it and Qiagen’s bioinformatics business are part of a consortium that has received €1.4 million ($1.7 million) in funding from a European funding initiative to support the development of software tools for personalized genetic analysis of cancer variants.
The Lungcadia program will combine the technologies and expertise of Cartagenia, Qiagen, and the Institute of Pathology at Hannover Medical School and will focus on lung cancer as a disease model, but the partners aim to make the results applicable to other types of cancer. The project has received the funding from the EuroTransBio initiative, which supports biotech collaborations in Europe.
The MdBio Foundation, Inc. (MdBio), a nonprofit organization, today announced that it has received a grant of $50,000 from AstraZeneca and its Gaithersburg, Md.-based global biologics research and development arm, MedImmune. The grant will enable the foundation to expand its focus on science, technology, engineering and math (STEM) education and prepare today’s students to become the workforce of tomorrow.
“Our goal is to show students the many possibilities their future can hold with a strong foundation in STEM,” said Brian Gaines, CEO of MdBio. “AstraZeneca’s and MedImmune’s generosity will enable us to expand our programs to ensure that we reach students who can benefit from enhanced educational opportunities. Our state is well-known for its strength in the bioscience market, and we hope to foster the next generation of employees for the companies that call Maryland home.”
Dr. William Kirwan, chancellor for the University System of Maryland, announced over the summer that he will be stepping down, but not until his replacement is hired.
He’s lost count of the number of college graduations he’s been a part of since taking the job as Maryland’s education chancellor more than a decade ago.
Johns Hopkins University, Biomedical Engineering, CBIDMonday, December 8, 2014 from 3:00 PM to 7:30 PM (EST)Baltimore, MD
Join us December 8th for a review of 16 exciting healthcare design projects at the Johns Hopkins Center for Bioengineering Innovation & Design (CBID). CBID MSE and Undergraduate projects will be presented. This year we’re honored to have as our Keynote Speaker Dr. John Kostuik. Dr. Kostuik is Co-Founder and Chief Medical Officer of K2M Inc, a world leading spine surgery company. The event will also have a Shark Tank competition with a panel of tough judges and real cash prizes. Refreshments will be provided.
The University of Maryland earned a gold medal in the International Genetically Engineered Machine competition (iGEM) held in Boston from Oct. 30 to Nov. 3, 2014.
The competition engages student-led teams from universities across the globe to present novel synthetic biology projects that address real-world problems.
The National Institute of Standards and Technology and the University of Maryland have collaborated to build a new center that will preform studies on how to store, process and transmit data using quantum architecture.
The Joint Center for Quantum Information and Computer Science is designed to complement basic quantum research being done at an institute run by NIST, UMD and the National Security Agency, NIST said Oct. 31.
Chevy Chase-based Wedding Wire, the largest and most trusted online marketplace connecting merchants with engaged couples and party planners, ranked highest of any other Maryland company this year, coming in at number seven with 2013 revenue of nearly $34 million. Also making the Top 10 is Rockville-based CoesterVMS, a leader in the mortgage banking and appraisal industry, coming in at number nine with $14.47 million in revenue in 2013.
Vheda Health, a digital health company that seeks to help people with chronic conditions, is one of a handful of healthcare startups that have received backing from a commercialization fund from Maryland’s Technology Development Corp. They were part of a list of 15 companies that received $1.5 million. It follows a funding allocation from earlier this year.
The Maryland program allocates funding to companies developing technology products with universities and/or federal labs in the state. To qualify, companies have to be in a collaboration with a federal lab or university, they have to be located in an affiliate incubator company in the state, they have to be involved in one of two Maryland programs — ACTiVATE, an entrepreneurship training program aimed at women, or INNoVATE — or participate in TEDCO’s Rural Business Initiative. The focus is on small businesses so companies must have under 16 employees, or be a university spin-off under five years old or have venture investments under $500,000. More than half of the companies’ employees must work in the state.
Business accelerator DreamIt Health Baltimore plans to lay roots in the Inner Harbor.
DreamIt Health Baltimore is negotiating a lease as it prepares to welcome its second class of entrepreneurs in 2015. The accelerator, which is run by Philadelphia-area DreamIt Ventures, operated out of spare office space at a Johns Hopkins building in Fells Point this year. Managing Director Jason Hardebeck hopes to finalize a deal for between 5,000 square feet and 6,000 square feet of space in the coming weeks.
Nominations are being accepted for the 2015 FLC Laboratory Director of the Year Awards. Sponsored by the FLC National Advisory Council, this award honors Laboratory Directors who have made maximum contributions to the overall enhancement of technology transfer for economic development. Accomplishments related to the transfer of technology from the federal laboratory to industry—including support of FLC activities, internal accomplishments, industry involvement, and community service—are the primary criteria for the award.
As CMS goes, so goes private insurance. That’s perhaps a simplification of how reimbursement rates are developed for healthcare payers, but big payers definitely watch what CMS is doing.
So it’s no small deal that CMS late last week issued new rules that include “significant additional coverage for telemedicine services,” the American Telemedicine Association said in a release.
When we think of Google, we think of the company that powers the widely used search engine, and we think of computer programming, engineering, and electrical design. However, recently Google has expanded and moved towards research in medical technology. Just a few months ago, the tech giant partnered with Novartis to license a glucose measuring smart contact lens. The company had also recently bought portions of Calico, an anti-aging research company, and 23andme, a company that provides personal genetic tests. Now, Google aims to develop a wearable diagnostic device to detect cancer and heart attacks through the use of nanoparticles.
Let’s face it: pre-Election Night, this year’s race for Maryland governor was pretty underwhelming, the kind where your mother might reveal she’s thinking of voting for Republican businessman Larry Hogan because she remembered his dad to be a nice guy back when he was Prince George’s County executive in the 1970s.
(Hi, Mom! For the record, I don’t know who she ended up voting for.)
University of Maryland University College recently swept two divisions of the Maryland Cyber Challenge for the second consecutive year, capturing first place in the College and Professional divisions of the premier Maryland cyber competition held at the annual Cyber Maryland conference in Baltimore.
“This is a tough competition and to beat many great teams just to get to the finals in the college and professional divisions is an amazing accomplishment. We fielded four teams for this competition (two in each division) and all four made it to the final round. That speaks to the quality of our teams, ” said Jeff Tjiputra, chairman of UMUC’s undergraduate cybersecurity program and academic advisor to the cyber competition teams.
The Pentagon’s technology arm is prepared to invest up to $700,000 in a promising idea in the field of biological sciences and technology. The goal is to turn theoretical concepts into actual products, such as better sensors for prosthetic limbs and techniques to cope with infectious disease outbreaks.
Under a new initiative by the Defense Advanced Research Projects Agency, inventors will be able to send in proposals without having to trudge through miles of red tape as they would have to in traditional government contracts.
The National Institutes of Health is challenging science innovators to compete for prizes totaling up to $500,000, by developing new ways to track the health status of a single cell in complex tissue over time. The NIH Follow that Cell Challenge seeks tools that would, for example, monitor a cell in the process of becoming cancerous, detect changes due to a disease-causing virus, or track how a cell responds to treatment.
The challenge aims to generate creative ideas and methods for following and predicting a single cell’s behavior and function over time in a complex multicellular environment – preferably using multiple integrated measures to detect its changing state.
Get out of the office and enjoy yourself! Join Maryland’s business community for an evening of networking and fun at the Tech Council of Maryland’s Fall Cocktail Reception. This reception will be held at the prestigious Congressional Country Club in Bethesda. If you haven’t attended our FEF Fall Reception, come and find out what you’ve been missing.
The reception features an open bar, great food and two hours with no agenda other than networking, seeing old friends and meeting new people. This is the perfect atmosphere for executives and decision makers from the region’s leading companies to come together and share ideas. Everyone is welcome and you don’t need to be a financial executive to attend this event, so register today.
The NBIA (National Business Incubation Association) seeks a dynamic new President and Chief Executive Officer. Our ideal candidate will be an exceptional leader with business expertise and a passion for entrepreneurship, as well as the drive, intellect, and professional presence to support and promote business incubation and acceleration.
The incoming President and CEO will report directly to the Board of Directors, and it is critical that this individual be well-versed in the broader national and international entrepreneur support ecosystem (including but not limited to business incubation, acceleration, coworking/emerging startup models, and economic environments – i.e. programs serving rural, urban, and developing economies).
iHealth is one of the leading developers of connected health devices, with devices on the market ranging from the BP5 connected blood pressure cuff to the Align wireless glucometer. As we recently highlighted, they have also been at the forefront of integrating the data captured by these devices with the electronic health records used by clinicians.
We had the opportunity to talk with Jim Taschetta, Chief Marketing Officer and Head of Retail Sales at iHealth, about their current work at Duke & Stanford exploring EHR integration, views on integration of Android devices, and more.
The Tax Foundation’s State Business Tax Climate Index enables business leaders, government policymakers, and taxpayers to gauge how their states’ tax systems compare. While there are many ways to show how much is collected in taxes by state governments, the Index is designed to show how well states structure their tax systems, and provides a road-map to improving these structures.
Inspired by a series of new strategic initiatives, BioNJ announced a rebranding today — BioNJ, The Gateway to Health – that reflects an expanded vision and mission directed to fostering a vibrant life sciences ecosystem in New Jersey where science is supported, companies are created, drugs are developed and patients are paramount.
The rebranding is supported by the launch of a revitalized website at www.BioNJ.org that is contemporary in its look and represents the determination of BioNJ to help move the life sciences industry forward.
Brain science is taking a hit, according to a recent series of papers published in a special issue of the Cell Press journal Neuron.
“While the disease burden and economic impacts are on the rise, progress in the development of new therapeutics and treatment approaches has appeared to have stalled,” reads an editorial introducing the issue. “Approval for new therapeutics (whether drugs, devices, or other treatment approaches) for nervous system disorders have been declining and most of the treatments we currently have are not disease modifying.”
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
Every once and a while you get a reminder that lives are literally at stake in some R&D partnerships. Last Wednesday was one of those days. I was privileged to moderate a panel for the Congressional Technology Transfer Caucus on innovative partnerships fostered by the National Center for Advancing Translational Sciences (NCATS) the newest center/institute at the National Institutes of Health. It was anything but a run of the mill tech transfer session.
We often hear that $2 billion to $5 billion are required to commercialize a new drug, with 14 years or more required for development and a 95% chance of failure. Less well known is that for thousands of serious diseases plaguing humanity only about 500 have FDA approved treatments available. Stark as that seems it’s downright cheery compared to rare or neglected diseases. Of more than 6,500 such ailments only 250 have treatments. While these may be “rare” diseases for many of us, to millions of our friends, families and neighbors each morning brings another day of suffering desperately hoping that someone, somewhere is working on a cure.
Paragon Bioservices, Inc. (“Paragon”), a privately held contract research and manufacturing organization whose mission is to accelerate the development and manufacturing of biopharmaceuticals and vaccines, announced today that it has raised $13 Million in a Series A Preferred Stock financing led by NewSpring Capital and Camden Partners.
NewSpring Capital, headquartered in Radnor, PA, invests in dynamic companies, partnering with management teams to accelerate growth and develop their businesses into market leaders. Camden Partners, located in Baltimore, MD, operates private equity funds that provide growth capital to emerging companies in the Technology-Enabled Business Services, Healthcare, and Educational sectors. 1st BridgeHouse Securities and Evergreen Advisors, LLC, Columbia, MD acted as advisors to Paragon Bioservices. All securities transactions were conducted through 1st BridgeHouse Securities, LLC, a member of FINRA and SIPC.
New Enterprise Associates is preparing to raise the largest venture capital fund in history, Fortune has learned.
The 37 year-old firm has told investors to expect formal documents by year-end for its fifteenth fund, which is expected to target approximately $2.8 billion. That’s nearly a 10% increase from the $2.6 billion NEA raised for Fund 14 in the summer of 2012, which itself was the industry’s record-holder (just edging out a $2.56 billion fund raised in 2006 by Oak Investment Partners). It also told prospective investors that longtime partner Scott Sandell will be promoted to co-managing partner, alongside Peter Barris.
Strand Life Sciences (Strand) representatives will demonstrate new capabilities of the company’s variant interpretation and reporting software, StrandOmics at the Association For Molecular Pathologist (AMP) 2014 Annual Meeting to be held from November 12th to 15th in National Harbor, Maryland. The 20th anniversary meeting’s theme is “Realizing the Dream of Precision Medicine,” with a special address by Dr. Francis Collins, Director of the National Institute of Health. At AMP, Strand will host a workshop on the innovative developments and application of its StrandOmics software, plus new expansion efforts in Personalized Medicine.
Baltimore pharmaceutical firm Profectus BioSciences Inc. has received a $9.5 million grant from the Department of Defense for a phase 1 clinical trial of its Ebola vaccine. T
he award is Profectus’ fourth this year — all for work developing and manufacturing Ebola vaccines. The new grant brings the company’s total funding up to at least $49.8 million.
The chancellor is stepping down. After 50 years in education, and 12 years as Chancellor of the University System of Maryland, William English “Brit” Kirwan is retiring. He will leave office after his replacement is selected by the Board of Regents.
The search is underway.
During his tenure, Kirwan was hailed for his strategic spending; his “Effectiveness and Efficiency Initiative,” started in 2003-04, has saved the system upwards of $462 million to date. He was also partly responsible for the tuition freezes after the recession. Under him, enrollment in Maryland’s 11 institutions of higher learning increased by 24 percent.
When it comes to deadly infections, Ebola is certainly the virus du jour. But in the U.S., the risk of contracting the Ebola virus is minuscule compared to the risk of becoming infected with one of several antibiotic-resistant bacteria, sometimes known as “superbugs.”
Novavax Inc.’s singular drug development approach to a possible Ebola vaccine may not only help stop the spread of a future pandemic but also reap major bottom-line rewards.
That’s what CFO Barclay “Buck” Phillips told me this week after the Gaithersburg-based company announced it planned to begin Phase 1 clinical trials by December. Novavax announced this week at the 8th Vaccine and ISV Conference in Philadelphia that it’s the only company targeting the newest strain of the virus which emerged in Guinea this year and has killed thousands in West Africa.
For five years, John Eldridge and his team at Profectus Bioscience have developed and tested their Ebola vaccine. First it was on guinea pigs, then monkeys.
At that point, Eldridge realized monkeys weren’t getting sick.
Johns Hopkins engineers have invented a lab device to give cancer researchers an unprecedented microscopic look at metastasis, the complex way that tumor cells spread through the body, causing more than 90 percent of cancer-related deaths. By shedding light on precisely how tumor cells travel, the device could uncover new ways to keep cancer in check.
The inventors, from the university’s Whiting School of Engineering and its Institute for NanoBioTechnology, published details and images from their new system recently in the journal Cancer Research. Their article reported on successful tests that captured video of human breast cancer cells as they burrowed through reconstituted body tissue material and made their way into an artificial blood vessel.
Montgomery County has chosen two partners to begin planning a “kitchen incubator” to provide business training and commercial kitchen space to budding local culinary entrepreneurs.
The county is partnering with Union Kitchen, which runs a for-profit commercial kitchen space in the District, and Streetsense, the Bethesda-based design and development firm, to plan how the incubator will be set up.
The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:
NIH Guide Notices:
Notice to Extend PAR-12-033 “Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Etiology, Diagnosis, Pathophysiology, and Treatment (R21)” by an Additional Funding Cycle (NOT-OD-15-007) Office of Research on Women’s Health
Notice of Clarification of 4-Year Limit of Postdoctoral Research Eligibility for K99 Applicants for PA-14-042 NIH Pathway to Independence Award (Parent K99/R00) (NOT-OD-15-013) Office of the Director, NIH
Notice of Revised NIH Definition of Clinical Trial (NOT-OD-15-015) National Institutes of Health
Requests for Applications (RFAs):
Pediatric HIV/AIDS Cohort Study (PHACS) Coordinating Center (CC) (U01) (RFA-HD-15-027) Eunice Kennedy Shriver National Institute of Child Health and Human Development Application Receipt Date(s): January 02, 2015
Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC) (U01) (RFA-HD-15-029) Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institute on Alcohol Abuse and Alcoholism National Institute of Allergy and Infectious Diseases National Institute on Drug Abuse National Institute on Deafness and Other Communication Disorders National Institute of Dental and Craniofacial Research National Institute of Mental Health National Institute of Neurological Disorders and Stroke Office of AIDS Research Application Receipt Date(s): January 02, 2015
NIH Director’s Early Independence Awards (DP5) (RFA-RM-14-004) NIH Roadmap Initiatives National Institute of Dental and Craniofacial Research Application Receipt Date(s): January 30, 2015
Please note that most links to RFAs, PAs, and Guide Notices will take you to the NIH Web site. RFPs will take you to FedBizOpps. Links to RFPs will not work past their proposal receipt date. Archived versions of RFPs posted on FedBizOpps can be found on the FedBizOpps site using the FedBizOpps search function. Under “Document to Search,” select Archived Documents.
Startup Maryland (www.startupmd.org) today announced the Great Eight (8) Finalists and three (3) Fan Favorites from the 2014 Pitch Across Maryland celebration.
After assembling more than 150 video pitches from Maryland entrepreneurs that were captured during the three-week Pitch Across Maryland tour | celebration, Startup Maryland is proud to announce the eight finalists as well as the three startups with the most view-votes. Companies from both categories are listed below (with tour stop) and link to their pitch video:
Inspiring the scientists of the future is something that MedImmune, the global biologics research and development arm of AstraZeneca, takes very seriously. Therefore the Society of Biology’s ‘Big Biology Day’ – a one day, free-to-attend event aimed at engaging the public in scientific issues and research activities – has become a permanent fixture in MedImmune’s calendar. This year’s event, which took place on Saturday 18th October at Hills Road Sixth Form College, was attended by over 1,000 people of all ages and was the third Big Biology Day to be held in Cambridge. As usual, it formed part of National Biology Week, the Society of Biology’s annual celebration of the biosciences and was held in collaboration with the University of Cambridge Science Festival.
Johns Hopkins University is the 11th best university in the world, according to the first ever Best Global University rankings published by U.S. News & World Report on Tuesday. The rankings use different criteria than those used for the annual “best colleges” list, on which Johns Hopkins ranked 12th last month.
The new rankings include 500 universities in 49 countries. Sixteen of the top 20 universities are in the U.S., including Harvard, which tops the rankings.
Silver Spring Civic Center-One Veterans Plaza GPS Address: 8525 Fenton Street, Silver Spring
Meet Israeli entrepreneurs working in Maryland and Maryland companies trading with Israel at the MIDCs fourth annual Showcase of Maryland/Israel Business. Featuring keynote speaker, Jeremy Bash,Founder and Managing Director, Beacon Global Strategies and former Chief of Staff, Department of Defense and CIA
American Tap Room – 36 Maryland Ave Rockville, MD 20850
Join BioBuzz and our sponsor CRB for another great BioBuzz networking event on November 19th from 5:00 – 7:30 p.m. @ American Tap Room in Rockville, MD. This location is a short walk from the Metro located in the Rockville Town Center.
CRB is a global consulting, design and construction services firm that relentlessly pursues and delivers success for their clients in advanced science and technology industries. 2014 marks CRB’s 30th year in which they have grown from a single three-person office, to a team of 600+ in 12 offices serving clients throughout the world with Rockville, MD being their latest expansion.
Maryland Department of Health and Mental Hygiene officials announced early Tuesday that the patient tested negative for Ebola. The department said that person will continue to receive the appropriate treatment.
A patient who was being isolated at the University of Maryland Medical Center in Baltimore for Ebola testing Monday evening does not have the deadly virus, officials announced Tuesday.
Advent Life Sciences today announced the closing of Advent Life Sciences Fund II (ALSF II), a £145.5M (USD 235M) venture capital fund raised to seed and build life sciences companies in the UK, Europe and the US. The Fund will back entrepreneurs and early-stage and mid-stage companies with the potential to deliver first- or best-in-class breakthrough products for unmet medical needs. The Fund, which quickly exceeded its target, was raised entirely from independent financial investors including funds-of-funds, pension funds, and family offices.
“We thank our returning and new LPs for the strength of their support, which allowed us to raise the commitments for this Fund in a matter of weeks” said Raj Parekh, General Partner. He added “The interest from LPs and demand for the Fund, particularly in current markets, is in large part a recognition of the scientific and medical entrepreneurs, CEOs and Management teams whose commitment, vision and energy is enabling our portfolio companies to bring important medical innovations to patients. It is a privilege to work with them.”
Two new studies in the New England Journal of Medicine rocked the world of celiac research, both proving that scientists have a ways to go in their understanding of celiac disease, which affects about 1% of the population, whether they know it or not.
One Italian study wondered if the age at which gluten is introduced into the diet could affect a person’s likelihood of developing the autoimmune disease—so they kept gluten away from newborns for a year. To the shock of the researchers, delaying exposure to gluten didn’t make a difference in the long run. In some cases it delayed the onset of the disease, but it didn’t stop people from developing the disease, for which there is no cure.
Cancer’s become a core area of venture capital interest, particularly given the rise of personalized medicine. But in a cluttered marketplace it’s tough to differentiate the worthy from the chaff. Here are some observations from a panel of investors said at the Cleveland Clinic Medical Innovation Summit Monday:
The San Francisco-based digital health accelerator Rock Health has raised a large third round of funding and says it will boost its investments in new portfolio companies to (up to) $250,000 each.
The new funding round was led by Bessemer Venture Partners and Kaiser Permanente Ventures, with participation from KPCB, Mayo Clinic, Montreux Equity Partners, and Great Oaks Ventures.
I’m so used to hearing bullish projections on digital health, it’s refreshing when someone contradicts that assessment. Maybe contradict is the wrong word. But Thomas Rodgers, who joined McKesson Ventures last month after a couple of years with Cambia Health Solutions, thinks it will take a lot longer for the technology to enjoy mainstream adoption.
“I think it will be 15-20 years until it is intertwined with medical care. It will take a shift away from fee-for-service and it will also take generational change. Millennials who grew up with technology will need to start getting sick.”
In the decade after the founding of the BioCrossroads initiative, money spent on life sciences research and companies more than doubled, to more than $25 billion, according to a new report released Thursday by the Indianapolis-based life sciences business development group.
That infusion of money—much of which came from out of state—has helped Indiana companies and universities increase the number of life sciences patents, technology licenses, startups and venture capital deals faster than the rest of the nation, according to the report.
The Hong Kong scientist who invented a simple blood test to show pregnant women if their babies have Down syndrome is now testing a similar technology for cancer.
Yuk Ming “Dennis” Lo says screening for signs of cancer from a simple blood draw could cost as little as $1,000. The test works by studying DNA released into a person’s bloodstream by dying tumor cells.
As Penn prepares for the ceremonial groundbreaking of the Pennovation Center on Friday, Drexel University’s Innovation Neighborhood is still searching for a master developer.
Both universities are pushing to become incubators of commercial enterprise and educational advancement. Since purchasing a 23-acre site on Grays Ferry Avenue in 2010, Penn has been working to develop the Pennovation Center — a three-story, 52,000-square-foot complex that will serve as a hub for research and business ventures. In addition to the ceremonial groundbreaking on Friday, Penn President Amy Gutmann will host a series of “Pennovation Talks” at the South Bank campus.
International VC firm SOSVentures is capitalizing on the now buzz worthy biotech investment trend with the creation of IndieBio, the first accelerator to focus on just life sciences.
Y Combinator raised a few eyebrows when it accepted five biotech companies out of the 80 startups in its program this last summer. That was a first for the Silicon Valley accelerator. But IndieBio partners tell us they were already thinking along those lines when Y Combinator started making in-roads with those life sciences startups.
The average board of directors in the biotech world is roughly 90% male, according to a new analysis, and more than half of all industry boardrooms host no women whatsoever, striking numbers that illustrate a sector that struggles with diversity.
Liftstream, a recruitment services outfit, analyzed nearly 1,150 life sciences companies in the U.S. and EU, finding that biotech’s boardrooms tend toward Y chromosomes. Among drug developers with fewer than 1,000 workers, women held just 10% of available board seats, and fewer than 4% had female chairs. C-suites didn’t fare much better, as women accounted for fewer than 25% of leadership teams across the industry.
UBI Index recognizes top performing business incubators from all over the world. This time we take a deeper look in 5 regional areas starting with Europe and then moving on to North America, South America, Asia+Oceania and ending with Africa. It is our pleasure to present to you:
The Regional Top Performing University Business Incubators of 2014
The rankings of each region will be announced every Tuesday at http://ubiindex.com/rankings with start on November 4th and four weeks forward. Stay tuned!
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
Sucampo Pharmaceuticals Inc. on Thursday named Peter Kiener — whose past roles includes CEO of Zyngenia and head of biologics R&D for MedImmune — as its chief scientific officer.
Kiener, a heavyweight research hire, worked alongside Sucampo CEO Peter Greenleaf at MedImmune, where Greenleaf served as president until early 2013. Kiener then departed to launch Zyngenia Inc., a New Enterprise Associates-funded biotech focusing on antibody-based therapeutics, which he departed last year.
Qiagen has announced the introduction of expanded functionality for its range of bioinformatics workflow solutions.
New capabilities for the Ingenuity Variant Analysis and CLC Cancer Research Workbench solutions were unveiled at the American Society of Human Genetics annual meeting, which recently concluded in San Diego.
Tuberculosis is both tough to treat and medically cumbersome to manage. Under directly observed therapy, a medical professional has to watch a patient take his or her medication for at least six months. A Baltimore health IT startup may help lighten that load.
The Baltimore City Health Department is launching a pilot with emocha Mobile Health’s app miDOT, according to a release from the Highlandtown firm.
The U.S. government invested $440 million in three vaccine plants in the U.S. in 2012 with the proviso that if something like a pandemic occurred, it could call on them to produce drugs that it required. With Ebola spreading, those calls have now been made.
The Ebola crisis has prompted the Biomedical Advanced Research and Development Authority (BARDA) to ask the three plant owners–Novartis ($NVS), GlaxoSmithKline ($GSK) and Emergent Biosolutions ($EBS) and their partners–to tell it what it would take for them to produce ZMapp, an experimental drug currently being produced through a novel approach using tobacco plants. BARDA wants detailed timetables and budgets for making ZMapp, Reuters reports. They are supposed to respond by Nov. 10.
Tania Fernandez came to the biotech initiative through the venture capital world, where she worked in Silicon Valley and spent 16 years managing investments in companies.
What is the biggest way your day will change in your new role? My day won’t really change. I am a classified workaholic. I will continue to do what I have always loved doing: working with entrepreneurs, building companies and looking for good investment opportunities in the biotech/life sciences/health care sectors. BioHealth Innovation has built a very commendable ecosystem for startups, and I look forward to the opportunity to build out that ecosystem with them as we get ready to fund raise for the BioHealth Gap Fund.
One thing you wish everyone knew about your job? I founded DreamCatcher Ventures after having spent more than 15 years in hard-core academics and a decade in venture capital financing. I have watched people get burnt either because they were not grounded enough (which translates into operational weakness) or had their head way above the clouds (which translated to being unrealistic about long-term success and sustainability of business models). I created DreamCatcher Ventures with a simple goal to “Build the foundations for dreams.” That’s what I want people to know about my job. This quote by Henry David Thoreau, which is the tagline for DreamCatcher Ventures, says it all: “If you have built castles in the air, your work need not be lost; that is where they should be. Now put the foundations under them.” For entrepreneurs there is a fine line between being stubborn and being persistent, an even finer liner between being a visionary and having unrealistic expectations. In my day-to-day job, I work with clients to bridge that. It is great to dream but you need to have your feet planted on the ground. I believe in the power of dreams combined with the excellence of execution.
Colleen Worthington has been working at this university for more than 24 years. It wasn’t until this year, however, that she received her first promotion.
“No matter how much better I got or more I contributed, it was the same title from 1990 until last [semester],” Worthington said.
Italian drugmaker Sigma-Tau is in advanced talks to sell part of its Italian operations to domestic peer Alfa Wassermann that would create an over-the-counter (OTC) powerhouse, several sources familiar with the situation said.
Sigma-Tau is working with Milan-based Four Partners, an advisory firm led by Sigma board member Guido Tugnoli, said the sources, who declined to be identified because the matter is private.
NewLink Genetics Corp (NLNK.O) said it entered into an agreement with Roche Holding AG (ROG.VX) to develop NewLink’s cancer immunotherapy, making the Ebola vaccine developer eligible to receive over $1 billion in milestone payments.
NewLink’s shares jumped nearly 30 percent before the bell on Monday.
Swiss pharmaceutical group Roche hopes to obtain fast-track US approval for a rapid diagnostic test for Ebola, its director general said in an interview published Sunday, amid the worst-ever outbreak of the killer disease.
The diagnostic test is ready for use in scientific research but the company now wants to register it for clinical use.
Pharma giant GlaxoSmithKline (GSK) might plan an initial public offering (IPO) of a minority stake in ViiV Healthcare, a global business focused on developing treatments for HIV, reports FierceBiotech.
Created five years ago, ViiV is GSK’s majority-owned joint venture with Pfizer and Shionogi. In the past 18 months, the Food and Drug Administration (FDA) approved two new HIV treatments from ViiV: Tivicay (dolutegravir) and the combo-tablet Triumeq, which includes Tivicay. These successes come at a time when GSK is planning to slash nearly $1.6 billion from its annual budget.
It’s no secret that Washington has a funding problem, with lawmakers and federal departments currently operating under unprecedented fiscal constraints.
It’s a very different story for the city’s entrepreneurs.
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, and Takeda Pharmaceutical Company Limited (Takeda) today announced that on October 17, 2014, they entered into a global license, development, commercialization and supply agreement for AMITIZA® (lubiprostone). Through this agreement, Takeda expanded its exclusive rights beyond the United States (U.S.) and Canada to further develop and commercialize AMITIZA in all global markets, except Japan and the People’s Republic of China.
“Takeda is committed to being a patient and customer-centric organization, making quality health products available to the patients who need them. Through this agreement, AMITIZA can now be made available to patients worldwide,” said Shinji Honda, Senior Managing Director and Corporate Strategy Officer. “Takeda forms partnerships to advance science and to provide innovative treatment options for patients, and this global agreement is an excellent example. This global collaboration leverages the expertise we have established through our gastroenterology portfolio of products.”
Baltimore biopharmaceutical company Profectus BioSciences Inc. has received a three-year, $8.5 million grant from the U.S. Army for work on an Ebola vaccine.
Profectus will share the grant with the Galveston National Laboratory at the University of Texas Medical Branch at Galveston. The grant is Profectus’ second in recent days. The company also announced a $5.8 million grant from the Biomedical Advanced Research and Development Authority (BARDA) to conduct safety studies of the company’s VesiculoVax, a potential Ebola vaccine.
The University of California recently announced its entry into the venture capital arena with a $250 million commitment to spinning promising technologies out of its top-notch, 10-campus system. Perhaps every major research university in the US — collectively, recipients of over $40 billion in federal research funding yearly, not to mention the inflows of corporate research funds — wishes to emulate Stanford’s success in capitalizing on the market successes of university-developed technology (think Google).
As a partner at Norwest Venture Partners (NVP), Casper de Clercq has seen countless digital health startups try to get solutions off the ground. He’s also seen many fail.
According to de Clercq, 60 to 70 percent of digital health startups are likely to fail because they are unclear about their go-to market strategy, and don’t have a good understanding of who’s ultimately going to pay for their product.
New initiative will support networks that help doctors access information and improve health outcomes
Health and Human Services Secretary Sylvia M. Burwell today announced an initiative that will fund successful applicants who work directly with medical providers to rethink and redesign their practices, moving from systems driven by quantity of care to ones focused on patients’ health outcomes, and coordinated health care systems. These applicants could include group practices, health care systems, medical provider associations and others. This effort will help clinicians develop strategies to share, adapt and further improve the quality of care they provide, while holding down costs. Strategies could include:
The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:
NIH Guide Notices:
Notice of Special Accommodations for Submission and Reporting Requirements for Program Directors/Principal Investigators Responding to the West Africa Ebola Outbreak (NOT-OD-15-010) Office of the Director, NIH
Notice to Extend the Response Date for NOT-OD-14-128 “Request for Information (RFI): Consideration of Sex As a Biological Variable in Biomedical Research” (NOT-OD-15-012) Office of the Director, NIH
Reminder: NIH Requires the Research Performance Progress Report (RPPR) for All Type 5 Progress Reports (NOT-OD-15-014) Office of the Director, NIH
Notice of Participation of the National Institute on Drug Abuse in PA-14-334 “Advancing Interventions to Improve Medication Adherence (R01)” (NOT-DA-14-052) National Institute on Drug Abuse
NHLBI Announces Frequently Asked Questions (FAQs) for RFA-HL-15-015 “Multi-Site Clinical Trials for the Pulmonary Trials Cooperative (U01)” and RFA-HL-15-016 “Network Management Core (NEMO) for the Pulmonary Trials Cooperative (U01)” (NOT-HL-14-240) National Heart, Lung, and Blood Institute
Please note that most links to RFAs, PAs, and Guide Notices will take you to the NIH Web site. RFPs will take you to FedBizOpps. Links to RFPs will not work past their proposal receipt date. Archived versions of RFPs posted on FedBizOpps can be found on the FedBizOpps site using the FedBizOpps search function. Under “Document to Search,” select Archived Documents.
Earlier this year, the Secretary of the Department of Health and Human Services (HHS) launched the HHS IDEA Lab. With it, we unveiled a consolidated structure for the innovation activities at the Department of Health and Human Services, flashy new branding and a website. But when we launched, we weren’t totally clear on what the main message for the HHS IDEA Lab was, and over the past 6 months we heard the question – what is the HHS IDEA Lab all about? So we have looked at ourselves, focused on what your needs are to solve problems, become an entrepreneur, or just learn new skills, and have clearly defined what the HHS IDEA Lab is.
In early drug discovery, you need a starting point, says Northeastern University associate professor of chemistry and chemical biology Michael Pollastri.
In a new research paper published Thursday in the journal PLOS-Neglected Tropical Diseases, Pollastri and his colleagues present hundreds of such starting points for potentially treating Human African trypanosomiasis, or sleeping sickness, a deadly disease that affects thousands of people annually.
The technology for creating new tissues from stem cells has taken a giant leap forward. Two tablespoons of blood are all that is needed to grow a brand new blood vessel in just seven days. This is shown in a new study from Sahlgrenska Acadedmy and Sahlgrenska University Hospital published in EBioMedicine. Just three years ago, a patient at Sahlgrenska University Hospital received a blood vessel transplant grown from her own stem cells.
Suchitra Sumitran-Holgersson, Professor of Transplantation Biology at Sahlgrenska Academy, and Michael Olausson, Surgeon/Medical Director of the Transplant Center and Professor at Sahlgrenska Academy, came up with the idea, planned and carried out the procedure.
Regression models, Monte Carlo simulations, and other methods for predicting what’s around the corner have been in use for decades. It’s only recently, though, that advances in information technology have made it possible for predictive tools to access and manipulate big data, and to do so continuously — accelerating the generation of insights, and opening up opportunities to anticipate issues with unprecedented precision. Think of the colleges that are increasingly able to identify students at risk of dropping out and intervene before they do. Or lenders’ enhanced abilities to gauge credit risk. Energy, agriculture, insurance, retail, human resources — no industry is unaffected. But nowhere is the potential of this new era of opportunity more apparent and exciting than it is in health care.
It’s not just the FDA that is making life difficult for medical device companies. Executives are having to follow sales opportunities as medical care shifts out of hospitals into homes and physician offices. They are having to revamp their entire business model to survive in the new world of the ACA.
A.T. Kearney has identified the five forces that are forcing the device industry to evolve in this new report: Medical Devices: Equipped for the Future? In addition to spelling out the threats, the analysts have a guide for how to start building a new business model.
Stapling up skin post-surgery is pretty much the norm to quickly seal up wounds, but it runs a risk of infection and injury from the extra damage to already sensitive skin.
Bay Area startup ZipLine Medical has developed a non-invasive but suture-like alternative that it’s positioning as a quicker, simpler and more desirable way to close small surgical wounds. To boot, clinical trials have shown the method decreases both infection likelihood as well as scarring. The company just closed a $5.7 million extension to its Series C financing round, led by a new venture firm in Shanghai called China Materialia that wants to expand the technology there.
Massachusetts General Hospital and MIT have formed a $3 million strategic alliance in an attempt to address three “major challenges” that persist in healthcare: improving diagnoses, developing new approaches to prevent and treat infectious diseases and developing more accurate methods of diagnosing and treating neurodegenerative and psychiatric diseases.
The alliance, officials said, will add further heft to already existing efforts between individual collaborations between the two institutions, particularly as they relate to development of diagnostic tools and therapies.
Roche plans to spend around $3bn updating and expanding its Basal site, home to the Swiss company’s headquarters, over the next 10 years.
The company is set to build a new R&D centre for 1,900 employees and an office building for 1,700 employees, and will also upgrade its existing infrastructure.
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
BioHealth Innovation clients Alex Lai (Speed BioSystems), Matthew Mulvey (Benevir), David Cetlin (MockV Solutions), and BHI Entrepreneur-in-Resident Ram Aiyar meet with Bahija Jallal.
Dr. Bahija Jallal is Executive Vice President, MedImmune, responsible for biologics research, development and clinical activities. As part of AstraZeneca’s Senior Executive Team, Bahija is tasked with advancing the biologic organisation’s pipeline of drugs targeting cancer, infections, respiratory and inflammatory diseases, cardiovascular and gastrointestinal disorders and pain. (Astrazenica Bio)
Biopharmaceutical company Emergent BioSolutions could begin manufacturing an experimental Ebola drug at its Baltimore facility.
Rockville-based Emergent is one of three advanced laboratories asked by the Biomedical Advanced Research and Development Authority (BARDA) to submit a plan for manufacturing ZMapp. The drug has been used among infected health workers in Africa but supplies have run out. BARDA will select one or more of the labs to make more of the drug.
Summary of Position: The Director, Regulatory Affairs is the regulatory representative on the Product Development Teams providing regulatory support and advice. The Director will facilitate regulatory strategy development and implementation, take the lead on regulatory submissions, and author, review, and coordinate quality submissions to regulatory agencies. The Director will prepare for meetings, teleconferences, and other communications with FDA, educate teams regarding regulatory risks and implications for strategy and product development activities, and utilize technical knowledge and effectively apply regulations and guidelines to the product development process.
Vanessa Sorto Accounting and Human Resources Intern
Vanessa Sorto joined BHI on September 2014 as an accounting and human resources intern. She is responsible for supporting the director of finance and human resources in assembling monthly expense reports for BHI senior staff, reconciling bank accounts, preparing monthly financial reports, assisting in audit preparation, and maintaining payroll. She is currently pursuing a bachelor’s degree at The University of Maryland, College Park in Accounting and Information Systems. She is a Hillman Entrepreneur scholarship recipient.
Kurt Herzog Business & Research Analyst
Kurt Herzog joined BHI in 2014 as a Business & Research Analyst. He assists BHI’s client companies with market entry strategies for their products by engaging with clients to understand current products, researching existing and potential markets, and analyzing business strategy. His work includes developing executive summaries, investor slide decks, tailored presentation materials, and creating financial models for presentation to investors.
Kurt also works with Tania Fernandez on the BioHealth Gap Fund, a $50 million fund announced October 2014 in partnership with the EAGB to support early-stage therapeutics, medical device, diagnostics, and health IT companies in central Maryland. Kurt has experience in investment banking, international micro-lending, renewable energy project finance and project development, forest carbon sequestration monitoring, institutional investing in hedge funds, and working for a non-profit startup accelerator. Kurt holds a BA in Economics and Environmental Studies with a Natural Science concentration from Bowdoin College. He also completed substantial coursework in chemistry.
Don’t miss the third annual full-day Innovation 2 Commercialization (I2C) conference featuring three informative plenary sessions to help launch, commercialize and fund YOUR technology to make your business venture profitable!
Hear panels on innovation, commercialization and financing featuring speakers from MedImmune, Brain Sentry, Naval Research Lab and more. Plus, learn about the “Amplimmune Story” and enjoy lunch as you discuss issues affecting your innovation or small business with a subject matter expert from a federal lab, university tech transfer office, venture capital firm, business service organization and others who serve as your table host.
Join the BioBuzz networking group at our next free event. Along with 100’s of the region’s bioscience workers, you too could be making new connections, getting jobs and helping to build a stronger, more connected industry through the BioBuzz community!
The event is always free and we offer free drinks to the first 50 to 100 who arrive depending on how much we’ve been sponsored on a given month. People from all around the the region are coming out each month for this unique and welcoming monthly happy hour. It’s a great place to meet up with coworkers past and present, make new connections or just catch up on the latest industry gossip If you’re new and haven’t yet made it out to an event, then we hope that you’ll join us this month and see what all the Buzz is all about.
One of the two Ebola-infected Dallas nurses was admitted to a National Institutes of Health biocontainment unit in Bethesda on Thursday, just as researchers at the University of Maryland School of Medicine in Baltimore are beginning the first human trials of an Ebola vaccine in Africa.
Dr. Myron Levine, a researcher at the medical school, is a member of the international medical group leading the efforts to end the outbreak. Ebola has infected more than 8,000 people since the first reported case in March, according to the Centers for Disease Control and Prevention.
Applications are now open for DreamIt Health’s second Baltimore cohort.
DreamIt Ventures will accept applications through Dec. 5, according to a DreamIt blog post. The first cohort last year included startups like Protenus, Aegle and Quantified Care.
ASTRAZENECA has announced a four-way collaboration which will strengthen the pharmaceutical giant’s link with Cambridge University.
The firm, together with its biologics research and development arm MedImmune, has agreed the new collaboration as it prepares to move its global headquarters to the city. It builds on an existing strategic partnership between the organisations.
The Tech Council of Maryland (TCM), Maryland’s largest technology trade association for life science and technology, has been awarded a three-year, $225,000 federal grant designed to help job seekers gain skills in the growing fields of cyber technology and cyber security.
The grant is part of a $15 million federal investment in the Cyber-Technology Pathways Across Maryland (C-PAM) Consortium, spearheaded by Montgomery College. The consortium, which is comprised of 14 community colleges and trade associations, aims to prepare women and other underrepresented populations for jobs in the rapidly growing cyber industry.
Sucampo Pharmaceuticals has announced that it signed an amendment to the existing collaboration and license agreement (Collaboration Agreement) covering the United States and Canada for AMITIZA(R) (lubiprostone) with Takeda Pharmaceutical Company Ltd. The amendment includes various modifications to the Collaboration Agreement including the extension of the current term, minimum commercial investment during the current term and various governance changes allowing Takeda additional flexibility in commercializing AMITIZA.
During the extended term, which will begin on January 1, 2021, Takeda will split with Sucampo the gross profits of branded AMITIZA for any dosage strength and form for the existing indications in the U.S. and Canada. In addition, on April 1, 2015 Takeda will no longer reimburse Sucampo for the product details made by Sucampo sales representatives to healthcare professionals as well as other ancillary costs of the sales force.
As the tech industry falls back in love with urban America, Joel Marcus, landlord to the booming biotechnology business, is perfectly positioned to strike it rich.
In Manhattan, overlooking the East River and sandwiched between New York University Langone Medical Center and Bellevue Hospital, two gleaming 16-story towers act as beacons to the booming biotech sector.
Completed in 2010, the 310,000-square-foot Alexandria Center for Life Science is already 100% occupied. It contains a hub for Eli Lilly’s cancer business and a Pfizer PFE -1.69% lab dedicated to exploring leads generated by academic researchers. The second building, some 410,000 square feet of labs and office space, was finished in January and is already 60% full. Roche, the anchor tenant, says moving 250 clinical trial specialists there from Nutley, N.J. has resulted in 25 new collaborations with charities, biotechs and New York hospitals. There’s also an accelerator for startups, an enviro-friendly garden and fancy restaurants to feed all those scientists.
Becton Dickinson (NYSE: BDX) has acquired GenCell Biosystems, a privately-held Irish biotech company that has developed proprietary technologies that address key biological analysis protocols – from library preparation of Next Generation Sequencing (NGS) to genotyping for agricultural applications.
“We are excited with the GenCell Biosystems acquisition as it provides BD entry into the Next Generation Sequencing market, a fast-growing segment with the potential to have a significant impact on healthcare,” said Linda Tharby, Group President, BD. “The acquisition gives BD access to the NGS market with a differentiated platform that will provide a base to further grow our genomics offerings.”
QIAGEN N.V. (NASDAQ: QGEN)(Frankfurt Prime Standard: QIA) announced today that its business area, QIAGEN Bioinformatics, has been named by Genomics England (GeL) an assessment winner for the UK100K project, along with other life science technology providers. The company will be providing project researchers access to Ingenuity® Variant Analysis™, a powerful web-application that allows users to rapidly identify and prioritize disease causing genetic variants using advanced analytics powered by published biological evidence and large numbers of sequenced genomes.
Bicycle’s founding venture capitalist (VC), Atlas Ventures joined forces this month with SV Life Sciences and three corporate VCs – Novartis (NVS) Venture Fund, GlaxoSmithKline’s (GSK) SR One and Astellas Venture Management to invest $32m (€25m) in the Cambridge-based biotech company.
Bicycle Therapeutics was established in 2009 as a spin-off of the Medical Research Council Laboratory of Molecular Biology (Cambridge), based on the work of the scientific founders Sir Gregory Winter and Professor Christian Heinis from Trinity College, Cambridge. Winter, a renowned scientist in the biotech industry, also founded Domantis and Cambridge Antibody Technology. Founded in the 80s, Cambridge Antibody Technology was a pioneer in British biotechnology, and was listed on the UK stock exchange in 1997, raising £43m. In 2006, AstraZeneca bought the company.
A $5 million Innovation Challenge Fund (ICF), to encourage and support academic groups and small companies in collaborative efforts in the development of bioelectronic medicines, has been announced by GSK. This funding programme is in addition to the company’s prior commitment of a $1 million award (December 2013), for the team that first solves the GSK Bioelectronics Challenge.
Bioelectronic medicine is focused on producing miniaturised, implantable devices that could be programmed to read and correct electrical signals passing along the nerves of the body, to treat disorders as diverse as inflammatory bowel disease, arthritis, asthma, hypertension and diabetes. The ICF funded work and the Innovation Challenge’s winning entry will be made freely available to the global research community.
Venture capital investments in Maryland are still working their way back up, according to a report released this week by PricewaterhouseCoopers and the National Venture Capital Association.
In the third quarter of 2014, venture capitalists spent $89 million, up 34 percent from the second quarter’s $66.5 million, but far off the third quarter number from last year, which hit $142 million, according to the report.
In the Boston-versus-New York rivalry, the Red Sox and the Yankees were also-rans this baseball season. Now, Massachusetts and New York are in another battle for the No. 2 spot: U.S. venture capital investment.
New York is leading Massachusetts in total venture capital invested so far this year, which if it held up would be the first time the Empire State edged out its East Coast rival and took second place behind industry leader California since at least 1992.
A BIOTECHNOLOGY company founded by Limerick man Kieran Curran has been snapped up for $150m by a US firm.
GenCell Biosystems, a company based in Raheen with offices in the US, was acquired late last week by Becton Dickinson, a company listed on the New York Stock Exchange.
ATCC, the premier global biological materials resource and standards organization, announces the release of ATCC® Minis to support quality control (QC) testing in pharmaceutical and industrial labs, during the PDA 9th Annual Global Conference on Pharmaceutical Microbiology in Bethesda, MD, Booth # 304.
Healthcare, personal care product, and cosmetic manufacturers are required to test the bio-burden and sterility of their products and production environments to ensure consumer safety. Global alignment and harmonization of microbial testing requirements among the United States Pharmacopeia (USP), Japanese Pharmacopeia (JP), and European Pharmacopeia (EP), have resulted in the need for consistent and reliable control organisms at less than five passages from the ATCC reference stock for reproducible results.
A jaw-dropping report released by the World Health Organization on October 14, 2014 reveals that 1 in 20 Ebola infections has an incubation period longer than the 21 days which has been repeatedly claimed by the U.S. Centers for Disease Control.
This may be the single most important — and blatantly honest — research report released by any official body since the beginning of the Ebola outbreak. The WHO’s “Ebola situation assessment” report, found here, explains that only 95% of Ebola infections experience incubation within the widely-reported 21-day period.
I joined J&J Consumer Companies about four years ago to start its Digital Center of Excellence. Our role initially was to build capabilities and develop strategy that served multiple brands in multiple regions, so I did a landscape overview to help develop the approach. What I saw was that we had hundreds of different websites and digital platforms that we were operating upon globally. If you want to get a message across globally on your owned assets, you need to do that in the same way across the world.
The Center for Innovative Technology (CIT) announced this week the release of the Commonwealth Research Commercialization Fund (CRCF) annual report for FY2014, showing growth in new patents, products and innovative companies.
Karen Jackson, Virginia’s Secretary of Technology, said, “CRCF plays an important role in the acceleration of innovation in the Commonwealth by funding essential research and commercialization projects. The investments we make in research commercialization plant the seeds that are growing the New Virginia Economy.”
Bioinformatics giant Illumina (NASDAQ: ILMN) is getting into the accelerator game, along with other players in the life sciences and other fields. On Wednesday it announced the first three startups chosen to start the program this fall at its San Francisco lab space.
San Diego-based Illumina, which makes genomic analysis systems, unveiled the program in February, joining the growing list of academic institutions, venture-backed groups, and life science corporations building start-up space in the Bay Area and beyond. Not least among the benefits of the Illumina accelerator program is access to the company’s high-end gene sequencing systems, which are installed in the lab space Illumina has leased near the Mission Bay campus of the University of California, San Francisco.
The Eastern Shore Entrepreneurship Center (ESEC), Rural Maryland Council (RMC), and Maryland Capital Entreprises (MCE) have joined together to offer the third annual Eastern Shore Business Competition. All three organizations strive to advance and expand the entrepreneurial ecosystem on Maryland’s Eastern Shore, as well as throughout Maryland, and collaborate to execute a business competition that will draw greater attention to the Eastern Shore and attract entrepreneurs to the opportunities and resources available in the region. The application process for the competition has begun and we are looking forward to your submissions!
The purpose of the competition is to promote and encourage the startup of new businesses and in turn the creation of new jobs on Maryland’s Eastern Shore.
Ideas are the juice that powers our economy with innovation happening fast on multiple technology fronts. Rapid developments are in play in areas as diverse as 3D printing, Ultra HD, sensors, health care, automotive electronics, agriculture, transportation, biotech and genetic mapping.
The $211 billion consumer electronics (CE) industry is at the vanguard of innovation. Just last year, the U.S. Patent Office issued a record 277,835 patents. We are at the beginning of a surge of technology advances that we will all benefit from.
On a massive bus in the heart of America, a group of tech entrepreneurs and investors are spreading glad tidings about entrepreneurship and startups in cities that don’t exactly scream innovation. Many people have tried to jumpstart the innovation engine across the country, but few have as much experience and clout to pull it off as Steve Case, co-founder of AOL, and chairman of DC-based investment firm Revolution.
Chairs: we sit in them, work in them, shop in them, eat in them and date in them. Americans sit for most of their waking hours, 13 hours every day on average. Yet chairs are lethal.
This grim conclusion may surprise you, but 18 studies reported during the past 16 years, covering 800,000 people overall, back it up. In 2010, for example, the journal Circulation published an investigation following 8,800 adults for seven years.
The National Institutes of Health (NIH) has launched a pilot program to help life science entrepreneurs commercialize their technology, based on a course developed by the University of California, San Francisco. The course was first taught last fall by the Entrepreneurship Center at UCSF and Steve Blank, architect of the Lean LaunchPad framework. UCSF and Blank adapted the Lean LaunchPad methodology to be applicable for life science and healthcare ventures.
Antibiotic resistance is taking its toll on the pharmaceutical industry: Drugs are getting retired from clinical circulation, because many are starting to get rendered ineffective, according to an article from Washington University of St. Louis. It highlights the work of WUSTL’s Michael Kinch, associated vice chancellor of its Center for Research Innovation in Business:
University of Maryland, Baltimore’s $200 million proton therapy center will begin treating cancer patients in a year.
The center’s first of five treatment rooms will begin treating patients in October 2015. The entire building is expected to be complete in two years. The 110,000-square-foot building is part of the University of Maryland BioPark in Baltimore off Martin Luther King Boulevard.
The Center for the Advancement of Science in Space (CASIS) has announced grant awards for three projects focused on enabling technologies from the International Space Station (ISS). These awards stem from the CASIS Request for Proposals (RFP) “Enabling Technology to Support Science in Space for Life on Earth.” CASIS is the nonprofit organization managing research onboard the ISS U.S. National Laboratory.
The purpose of this RFP was to identify and support technology development projects that would enable increased use of ISS for Earth benefits—for example, improvements in hardware/capabilities or methods to improve bandwidth, throughput, or quality of future research projects.
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
Dutch biotech MIMETAS B.V. announces that it has raised 5.2 million dollar to fund its expansion as a global leader in organ-on-a-chip technology. Venture capital investors Zeeuws Investerings Fonds (ZIF) and Participatiemaatschapij Oost Nederland (PPM Oost) have joined forces with national and regional partners to fund development and sales of MIMETAS’ unique 3D disease- and tissue modelling technologies.
Jos Joore, co-founder and Chief Business Officer of MIMETAS, acknowledges that these resources arrive at a strategically important moment: “Collaborations with top-tier pharmaceutical companies are expanding rapidly, an example of this is the recently announced 1.6 million dollar kidney-on-a-chip project with Roche, Pfizer and GlaxoSmithKline. The funds will be used to scale up the production of OrganoPlates™ and strengthen our activities in predictive preclinical model development, thus consolidating our leadership in this highly competitive field.”
Please join BioHealth Innovation and the National Institutes of Health in a session to learn more about the Small Business Innovation Research (SBIR) program, one of the largest sources of early-stage capital for innovative small companies in the United States. SBIRs are non-dilutive federal research and development grants and contracts that fund innovative research efforts intended for commercialization by small business
This free event brought to you by BioHealth Innovation allows you to hear directly from the largest NIH Institutes on what they are looking for in a high quality grant application. These Institutes include the National Cancer Institute (NCI), National Heart Lung & Blood Institute (NHLBI), National Institute of Allergy & Infectious Disease (NIAID), and the National Institute of Neurological Disorders & Stroke (NINDS).
After remarks from each Institute, we will break out into a speed networking session to talk about your project with program managers.
Contact Ethan Byler at ebyler@biohealthinnovation.org if you are interested in scheduling one-on-one meetings.
Don’t miss the third annual full-day Innovation 2 Commercialization (I2C) conference featuring three informative plenary sessions to help launch, commercialize and fund YOUR technology to make your business venture profitable!
Hear panels on innovation, commercialization and financing featuring speakers from MedImmune, Brain Sentry, Naval Research Lab and more. Plus, learn about the “Amplimmune Story” and enjoy lunch as you discuss issues affecting your innovation or small business with a subject matter expert from a federal lab, university tech transfer office, venture capital firm, business service organization and others who serve as your table host.
The patent covers novel MDCK cells that have been adapted to grow in serum-free culture medium as well as cultivation techniques MedImmune uses to increase vaccine production titres.
According to the patent the modified cells support replication of attenuated influenza virus to a log10 TCID50/mL of at least 7, which is a significant advance on previous highest viral titres – around 4 log10 TCID50/mL – described in the literature .
Joel S. Marcus, founder, chairman, and chief executive of Alexandria Real Estate Equities, has focused the real estate investment trust on developing properties for the life sciences industry. While it operates in other biotechnology and medical technology hubs from New York to San Francisco, the Pasadena, Calif., company’s largest cluster of properties is in Greater Boston, where it owns 3.5 million square feet of space in Cambridge’s Kendall Square, along Route 128, and in Boston’s Longwood Medical Area. On a visit to Cambridge, the 67-year-old Marcus spoke with Globe reporter Robert Weisman. Here’s what he found out:
As Alexandria Real Estate Equities (NYSE: ARE) marks the 20th anniversary of its founding, the provider of state-of-the-art real estate for the science and technology industries is seeing occupancy, demand and new development all reach record levels.
“It’s an interesting time because we’re seeing the innovation economy doing miraculously well,” said Joel Marcus, founder and CEO of Pasadena, Calif.-based Alexandria.
MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…
In order to access this content you need to be logged into the site and have an active subscription or trial subscription. Please login, take a free trial or subscribe in order to continue reading.
Swiss drug major Roche (ROG: SIX) has acquired exclusive rights to a primer extension-based target enrichment technology and associated patent applications filled by therapeutic target discovery company AbVitro.
AbVitro and Roche scientists are to collaborate on the development and application of the technology, which will be used to support next-generation sequencing directly from blood or other biological samples, a key advantage for clinical sequencing applications. It will be incorporated into Roche’s sequencing unit research and development pipeline to support the strategy of providing a full next-generation sequencing workflow solution for clinical sequencing.
Join the BioBuzz networking group at our next free event. Along with 100’s of the region’s bioscience workers, you too could be making new connections, getting jobs and helping to build a stronger, more connected industry through the BioBuzz community!
The event is always free and we offer free drinks to the first 50 to 100 who arrive depending on how much we’ve been sponsored on a given month. People from all around the the region are coming out each month for this unique and welcoming monthly happy hour. It’s a great place to meet up with coworkers past and present, make new connections or just catch up on the latest industry gossip If you’re new and haven’t yet made it out to an event, then we hope that you’ll join us this month and see what all the Buzz is all about.
A Johns Hopkins neuroscientist hopes to fuel future research projects by turning his expertise into a video game that stars a dolphin.
Hopkins neuroscientist John Krakauer, who studies movement and human obsession with movement, worked with Hopkins software architects Omar Ahmad and Promit Roy, and Baltimore artist Kat McNally to create the game “I Am Dolphin.” The game was released through iTunes Oct. 9 and costs $2.99.
The University Senate made progress on the policies and guidelines that address non-tenure-track faculty — or professional track faculty, as they will soon be addressed, after a proposal passed in the senate yesterday.
The proposal, which passed by a vote of 61–12 with four abstentions, aims to create an overall title for faculty who are not on the tenure track but contribute to the university through teaching, research or service.
The National Institutes of Health on Thursday awarded almost $32-million in grants to more than two dozen institutions to devise innovative ways of helping researchers handle huge sets of data seen as increasingly central to future medical discoveries.
The grants are the first outlay in a project, announced last year and known as Big Data to Knowledge, that’s expected to involve more than $600-million in spending by 2020. Its goals include developing and distributing methods, software, and tools for sharing, analyzing, managing, and integrating data into medical research.
In 2014, startups took home nearly $1M in cash and prizes from the InvestMaryland Challenge. For 2015 we have new categories and are racking up partner prizes like cash grants, incubator space, legal advice and consulting services.
IT HARDWARE/SOFTWARE Enterprise Software, Data Analytics, Social Media & Apps, E-Commerce and Marketing/ADTECH.
DEFENSE & SECURITY Cybersecurity, Unmanned Systems, Defense, Communications Infrastructure, Public Infrastructure and Grid Security.
LIFE SCIENCES Biopharmaceuticals, Medical Devices & Diagnostics, Nutraceuticals, Agriculture Bio & Aquaculture and Healthcare IT.
SUSTAINABILTY & EXPLORATION EdTech, Energy, Solar Power, Space & Satellite Technologies, Climate Change/Weather, Water Management and Materials Science.
Nominations are now being accepted for the 2015 FLC Awards. Since its inception in 1984 the FLC Awards have become one of the most coveted honors in the technology transfer field, with over 200 Federal laboratories honored for their work in projects that advance the mission of technology transfer. To reflect the diversity in scope and number of technology transfer efforts undertaken by federal laboratories and their partners, seven categories of awards will be presented:
A California-based business accelerator that considers applicants based on their test scores is considering launching a Baltimore chapter.
Founder Institute already operates in 61 cities, and now it’s looking for its first Baltimore class. Local organizers will be hosting events throughout the month of October to determine whether any local entrepreneurs meet their standards – talented folks who would be a part of the four-month program that would start later this year or toward the beginning of 2015.
A business accelerator that admits people based on their entrepreneurial potential — not just their business idea — is looking for its first Baltimore class.
Founder Institute, a California-based organization that operates accelerator program in 61 cities, is considering launching a Baltimore chapter. Local organizers will be holding engagement events in October to gauge interest and determine if any local entrepreneurs are good candidates. The four-month program could start later this year or early next.
The ETC (Emerging Technology Centers) www.etcbaltimore.com,Baltimore City’s award-winning technology innovation centers, announced today that The Abell Foundation will continue its support of AccelerateBaltimore™for 2015. Six companies will be selected for this intensive 13- week program and will be awarded $25,000 each to help propel their business ideas forward.
“We are absolutely thrilled that The Abell Foundation is continuing its support of AccelerateBaltimore (AB),” said Deborah Tillett, ETC’s president. “Of the 16 companies to successfully complete the program, 81% are still in business and have raised over $2.5 million in follow-on funding.”
A pilot program launched this week in four NIH institutes looks to speed up development and commercialization of new products and services generated by projects funded through the agency’s Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) awards.
The first class of 21 three-person teams of researchers and entrepreneurs gathered in Chevy Chase, MD, this week, concluding Wednesday, for the launch of the NIH Innovation Corps (I-Corps™) Team Training Pilot Program. The teams are all based at therapeutics, diagnostics, and medical devices companies funded with NIH SBIR Phase I grants, awarded to establish feasibility of proof of concept for commercializable technology.
For more than 3,000 years, traditional Chinese medicine was the predominant medical treatment in China. In recent decades, the practice has gained popularity in the the west.
Herbal medicines and various mind and body practices, such as acupuncture and tai chi have become a fashionable way to treat or prevent health problems.
An ancient practice finds its place in modern society. This is the Beijing Chinese Medicine clinic in Santa Monica, Los Angeles.
T, business, human capital and other stakeholders can now use cloud-based analytics to more effectively attract, acquire, serve and engage customers, Deloitte Digital announced today. Deloitte Digital has created an analytics offering for Wave, the Salesforce Analytics Cloud that is designed to offer greater flexibility than on-premises solutions. Deloitte Digital’s approach to cloud-based analytics is designed to help companies create strategies for success in a new environment. An example of Deloitte Digital’s commitment to Salesforce Analytics Cloud is its Member Connect solution, a health care industry-focused accelerator with an intuitive approach to the customer journey focusing on omni-channel interactions and a holistic view of the customer.
Of the 115 healthcare accelerators in the world, 87 are in the U.S., most of them are geared to digital health and are under two years old. Although many accelerator companies have created jobs and there have been some exits, most have yet to show anything for the investment in them. That’s understandable given the age of the average accelerator and given that it can take seven years before a company can realize a return on capital for investors. But the consensus of a new report published by the California HealthCare Foundation is that we should expect some consolidation soon.
Downtown Partnership of Baltimore Inc. is launching a grant program aimed at getting more tech firms to consider moving downtown.
The nonprofit is offering six $10,000 grants to tech firms willing to give office space a try downtown for at least a year. Firms must locate to within Downtown Partnership’s “management authority area,” a 106-block area that includes the central business district, part of midtown’s west side and the west side of downtown up to Greene Street.
While all The Seven Habits of Highly Effective People listed by Stephen Covey remain relevant and timeless, the one which resonates with me most is the seventh — sharpen the saw. In the life sciences industry, Covey’s concept of continuous improvement is more than just a habit, but a way of life. This is especially true for those who work in pharma and biopharma manufacturing — striving to maintain high quality, be on time with delivery, increase productivity (often with fewer resources) and so on. If you work in manufacturing, you are probably tempted to stop reading and get back to work.
Health information technology (HIT) refers to a broad spectrum of technologies, ranging from personal health-monitoring applications to big data analytics. The venture capital firm Rock Health recently reported that venture capital funding in the HIT field reached $3 billion for 2014, well surpassing the $1.9 billion invested in the sector during 2013.[1] The LSN research team tracks investors in early stage life sciences, and we have noticed a growing interest in HIT as well.
Mayor Vincent C. Gray, Interim Deputy Mayor for Planning and Economic Development M. Jeffrey Miller and DC Innovates today announced grants for eight tech startups through the Digital DC Tech Fund (DDCTF). DDCTF is a catalytic fund that provides grants of $25,000 to $200,000 along with a customized mentorship program for early- and growth-stage technology ventures in the District of Columbia.
“Each of these grantees represents a bright future for technology, innovation and economic growth in the District of Columbia,” Mayor Gray said. “Through the Digital DC Tech Fund, my administration is able to provide resources and opportunities that will allow grant recipients to grow their companies and continue to make the District a place where innovative companies can start, develop and thrive.”
For creative writing, Joyce Carol Oates got it right when she advised, “Be daring, take on anything.”
But when you are trying to make a good first impression on you future boss, concision and confidence sets a qualified applicant apart from one who doesn’t sound sure of her own experience.
Andrew Laver has long worked with life science startups through his work as an angel investor, venture capitalist and investment banking. Now he’s getting that perspective from one of Healthbox’s newest accelerators in Salt Lake City.
As I mentioned in another post, it’s interesting that an accelerator would take on so many medical device companies (four). But as Laver points out, it goes with the territory because there are so many in the region. Salt Lake City has the biggest concentration of medical device manufacturers in the country, according to Utah’s economic development corporation. It has more than 100 medical device companies.
Failure to diagnose the Ebola case quickly in Texas raises questions about electronic health records, known as EHRs.
Information entered by a nurse was not transferred to doctors in an emergency room. With more of our medical records going digital, failures in the relatively new technology will become more important to all of us.
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today that venture capitalist, Tania Fernandez, Ph.D., has joined the BHI team as a strategic advisor. Dr. Fernandez will be a member of the management team for a new BioHealth Gap Fund, which will provide up to $50 million in seed and early-stage equity investments to therapeutics, medical device, diagnostics, and health IT companies in Maryland. Additional BioHealth Gap Fund management team members include Richard Bendis, Ram Aiyar, Todd Chappell, and Ken Malone, who each bring domain knowledge and industry access to the fund.
“Dr. Fernandez has ten years of experience as a venture capitalist in the life sciences/biotechnology industry. Her work in Silicon Valley, along with her research experience at the National Cancer Institute, makes her a tremendous asset to the BHI team,” said Richard Bendis, BHI President & CEO. “Dr. Fernandez brings a West Coast investment perspective, and she will have an active role in helping to manage the BioHealth Gap Fund. She will also support our BHI Entrepreneurs-in-Residence and clients: helping our startups to grow and raise strategic funding.”
The next generation of the nation’s only anthrax vaccine will be made in Lansing, an executive for Emergent BioSolutions Inc. said Tuesday.
There won’t be any new jobs as a direct result of the $29 million federal contract Emergent received earlier this month for production of the new drug, Adam Havey, president of the company’s biodefense division, said. But the new version of the vaccine will help keep current employees working.
For the majority of drugs, end-of-lifecycle planning usually involves a reining-in of marketing costs. But Sucampo CEO Peter Greenleaf is doing the exact opposite. In the firm’s second-quarter earnings call, he announced the company is “doubling-down” on Amitiza, the constipation treatment which has been on the market for eight years and which will soon face the threat of generic competition.
Amitiza owns just 1% of the overall constipation market, which includes a number of OTC options, a representative for the drugmaker told MM&M. Sucampo co-markets Amitiza with Takeda.
Medical equipment supplier Becton Dickinson & Co (BDX.N) has agreed to buy CareFusion Corp (CFN.N), a maker of infusion pumps and other medical devices, for $12.2 billion in cash and stock, marking the latest multibillion-dollar healthcare sector deal.
Becton said on Sunday it would pay a total of $58.00 a share – $49.00 in cash and 0.0777 of a share of Becton Dickinson – for each share of CareFusion, representing a premium of 26 percent to the closing price on Oct. 3.
Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give an insight into the commercial potential of the candidate once it is successfully developed and commercialized.
Roche (RHHBY – Analyst Report) specializes in cancer drugs. Immunotherapy has received a lot of attention in recent times as pharmaceuticals majors focus their research and development efforts on the same.
GlaxoSmithKline has just launched a $5 million Innovation Challenge Fund to advance open-access technology in the bioelectronics space.
The funding’s aimed toward biz-savvy academics and startups that are working to create a new class of treatments that aren’t necessarily pills or injections, but rather are mini implantable devices. GSK says:”The hope is that these devices could be programmed to read and correct the electrical signals that pass along the nerves of the body, to treat disorders as diverse as inflammatory bowel disease, arthritis, asthma, hypertension and diabetes.”
University of Maryland, Baltimore County, and University of Maryland, College Park will work with MITRE Corp. on a new cyber security research and development center in Montgomery County.
McLean, Va.-based MITRE was selected by the National Institute of Standards and Technology for a $29 million award to operate a new federally funded research and development center dedicated to cyber security. The center will be housed at the National Cybersecurity Center of Excellence in Montgomery County.
Tasly Pharmaceuticals, Inc. made its official debut at the Natural Products Expo East 2014, held from September 17-20, 2014 in Baltimore, MD. As the leading East Cost trade show in the natural, healthy and organic products industry, attracting 22,000 professionals and representing 33% of the natural products industry, Expo East 2014 was a perfect opportunity for Tasly to introduce Deepure, its inaugural line of nutraceuticals. The line includes three condition-specific, whole-food and herb-based formulas, namely, ProHeart PLUS, ImmunoPower PLUS, and Re-Memory PLUS. All Deepure nutraceuticals are gluten-free and made without chemicals, preservatives, artificial colors, flavors, sweeteners, or gelatin. Deepure will be available in stores nationwide later this Fall.
Tasly also participated in two very attractive marketing and sponsorship opportunities located in New Products Pavilion, including Best of East Press Showcase and New Products Showcase.
ROCKVILLE AND BALTIMORE, MARYLAND, September 30, 2014 – BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today that venture capitalist, Tania Fernandez, Ph.D., has joined the BHI team as a strategic advisor. Dr. Fernandez will be a member of the management team for a new BioHealth Gap Fund, which will provide up to $50 million in seed and early-stage equity investments to therapeutics, medical device, diagnostics, and health IT companies in Maryland. Additional BioHealth Gap Fund management team members include Richard Bendis, Ram Aiyar, Todd Chappell, and Ken Malone, who each bring domain knowledge and industry access to the fund.
“Dr. Fernandez has ten years of experience as a venture capitalist in the life sciences/biotechnology industry. Her work in Silicon Valley, along with her research experience at the National Cancer Institute, makes her a tremendous asset to the BHI team,” said Richard Bendis, BHI President & CEO. “Dr. Fernandez brings a West Coast investment perspective, and she will have an active role in helping to manage the BioHealth Gap Fund. She will also support our BHI Entrepreneurs-in-Residence and clients: helping our startups to grow and raise strategic funding.”
Dr. Fernandez previously was a venture capitalist with Burrill & Company, a $1.5 billion fund with a portfolio of 103 companies in the biotechnology/life science industry. Dr. Fernandez has over sixteen years of industry experience with the ability to successfully identify and assess promising scientific technologies/products and business models for venture investments across the sectors of therapeutics, diagnostics, next-generation sequencing and healthcare delivery. She has led and managed investments through both operational and Board positions. Roche acquired her lead investment, Bioimagene, for $100 million within two years of investment. Dr. Fernandez plays an active role in training and mentoring entrepreneurs in Silicon Valley and provides strategic advisory services to companies that range from startups to revenue-driven companies.
BHI’s BioHealth Gap Fund is anticipated to be a $50 million fund that will invest in disruptive companies throughout Central Maryland looking to close the gap between seed and early-stage financing. The fund will focus on therapeutics, medical devices, diagnostics, and health IT companies, and provide seed and early-stage equity investments along with follow-on capital for growth to help companies exit successfully.
“It is an honor to have the opportunity to work with BHI and to help manage the new BioHealth Gap Fund,” said Dr. Fernandez. “The potential to serve a pressing need in the current life sciences funding landscape in Maryland is tremendous, and I am delighted to be a part of it.”
About BioHealth Innovation, Inc. BioHealth Innovation, Inc., is a regional innovation intermediary focused on commercializing market-relevant bio-health innovations and increasing access to early-stage funding in Maryland.
On September 10, 2014, Tasly Pharmaceuticals, Inc. (Tasly) and BioHealth Innovation, Inc. (BHI) signed a Memorandum of Agreement (MOA) which aims to advance their business partnership. The MOA also lists specific near- and long-term collaboration activities between the two parties.
U.S. Senators Ben Cardin and Barbara A. Mikulski (both D-Md.) today announced that the Department of Labor (DOL) has awarded $14,957,899 in federal funding to fourteen Maryland community colleges as part of the Trade Adjustment Assistance Community College and Career Training (TAACCCT) initiative. The TAACCCT program allows community colleges and other institutions to expand their ability to provide quality education and job training programs in two years or less.
Of the nearly $15 million, Montgomery College received $5,371,743 to lead and fund the Cyber- Technology Pathways Across Maryland (CPAM) Consortium. CPAM is comprised of fourteen Maryland community colleges. It seeks to train and educate Trade Adjustment Assistance workers, veterans, the un- and –under employed and low skilled adults. The Consortium will work to connect participants with employers looking to fill thousands of unfilled job openings. CPAM focuses on bringing women and other underrepresented populations into the growing fields of cyber technology and cyber security.
This event is to gather interested small businesses seeking assistance from the Small Business Innovation Research grants program from the National Institutes of Health. This is a free event brought to you by BioHealth Innovation. Hear from the SBIR managers on current Institute funding priorities. Meet one-on-one with program managers regarding your current project. Learn of SBIR assistance provided by BioHealth Innovation.
At the forefront of innovation, the Consumer Electronics Association (CEA) unites 2,000 companies in the consumer technology industry and owns and produces the world’s largest annual innovation tradeshow, the International CES®. Gary Shapiro, the president and CEO of CEA, knows innovation and is the go-to source to tell you what’s cool in consumer electronics. Ask him what’s in this year and he’ll talk about Ultra HD 4K TV, 3-D robotics, and wireless health. He’ll also mention that the biggest drivers of consumer electronics are products that didn’t even exist a few years ago. Join Gary as he takes you on a spirited discussion about the importance of innovation in the U.S. economy, green technology, and keeping the American dream alive.
Get a look inside Shapiro’s passion for innovation and see what it’s like to be at the forefront of a multi-billion dollar industry.
Tuesday, October 7, 2014 from 6:00 PM to 8:00 PM (EDT)
Rockville, Maryland
In February 2013, The Sunshine Act was included as the Transparency Reports and Reporting of Physician Ownership or Investment Interests section of the Patient Protection and Affordable Care Act (ACA). The Sunshine Act requires manufacturers of drugs, medical devices, and biologicals that participate in U.S. federal healthcare programs to report certain payments and items of value (typically $10 or more and totaling $100 annually or greater) given to physicians and teaching hospitals. Failure to stay in compliance may result in fines ranging from $10,000 to $1,000,000 annually. Whether you are a practicing physician or your startup has a medical device, drug, or related product, you are impacted by the ACA’s Physician Payments Sunshine Act. In July, CMS proposed removing the reporting exemption for any payments or transfers of value made to physicians who participate in accredited CME programs. We’ll talk with experts in compliance and policy who will share their experiences in implementing these new policies and how you can understand the implications of the law, dispute inaccuracies, and stay in compliance!
The DC I-Corps Fall 2014 Regional Cohort officially kicks off on October 9th at the Microsoft building in Chevy Chase, MD. Please register to join us for our Showcase lunch, in which successful teams from previous cohorts will present their businesses and discuss lessons learned from the I-Corps program.
Showcase agenda:
Welcome and lunch
Introduction of incoming Fall cohort teams
Presentations by Accelerator teams
Q&A
About DC I-Corps: DC I-Corps is a regional program designed to foster, grow and nurture an innovation ecosystem in the nation’s capital, the nearby states of Maryland and Virginia, and the mid-Atlantic region. The program is sponsored by the National Science Foundation (NSF) and jointly run by the University of Maryland College Park, George Washington University, Virginia Tech and Johns Hopkins University. The program provides real world, hands-on training on how to successfully incorporate innovations into successful products. The ultimate goal is to create a new venture or licensing opportunity for program participants.
The National Institutes of Health and the U.S. Food and Drug Administration will receive a top national award for the year’s most outstanding intellectual property licensing deal, for technology transfer of a pioneering, low-cost meningitis vaccine launched in sub-Saharan Africa. The 2014 Deals of Distinction Award will be presented to the two federal agencies and their collaborators by the Licensing Executives Society at the society’s 50th annual meeting, Oct. 5-8 in San Francisco.
Johns Hopkins University named Leslie Ford Weber director of campus, government and community affairs for Montgomery County in Rockville.
She succeeds Elaine Amir, who retired in September 2013.
Weber had been interim executive director of the campus since October and director of government and community affairs for Suburban Hospital in Bethesda since July 2011.
Wednesday, October 1st, is the deadline to apply for the next round of BioMaryland Center biotechnology development awards. The BioMaryland Center is partnering this year with Maryland’s Dept. of Health and Mental Hygiene (DHMH) and the Center for Medical Technology Policy (CMTP) to incorporate improved health care quality and cost reduction criteria in the selection process for the Center’s annual Awards program.
A total of $1M will be awarded on a competitive basis to projects, $50,000-200,000 each, advancing technologies toward commercialization–with preference given to projects which improve patient outcomes and reduce costs.
BioMaryland, DHMH and CMTP will provide ongoing advice and support to the teams whose projects are selected for funding to address technical, scientific, regulatory and reimbursement issues that may be encountered during the development process.
Nationally, young firms play a central role in the creation of new employment opportunities. High-tech companies are particularly important to job creation: over 9% of average annual net job creation from 1990-2011 is due to high-tech firms younger than 5 years old. All private firms younger than 5 years old created less than 6% of average annual net job creation.
Young, innovative companies have generated the majority of new jobs in Greater Baltimore over the past 5 years. This trend is consistent with similar metropolitan regions and the coun- try as a whole. New technologies, research, and ideas spawn new teams, divisions, and entire companies. Continuing to support and encour- age innovation is imperative to sustaining growth in the Greater Baltimore economy.
Circulomics Inc has been awarded a Phase I Small Business Innovative Research (SBIR) grant by the National Institutes of Health (NIH) to develop its Nanobind DNA and RNA isolation technology for formalin-fixed, paraffin-embedded (FFPE) samples. This grant was made by the National Institute of Environmental Health Sciences to create a novel method for extracting molecular information from archived tissues. FFPE sample archives contain a wealth of molecular biomarker information that can be compared to standard histological analysis and correlated to clinical outcomes. However, the DNA and RNA isolated from FFPE samples are often degraded due to damage from the FFPE preservation process as well as contaminated by residual formalin and paraffin wax.
Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of the pivotal non-clinical efficacy study to demonstrate that BioThrax® (Anthrax Vaccine Adsorbed) manufactured at large scale in the company’s new modern facility, Building 55, is comparable to the BioThrax currently manufactured in its approved facility, Building 12. Data from this study will be used to support licensure of Building 55. BioThrax is the only vaccine licensed by the U.S. Food and Drug Administration (FDA) for the prevention of anthrax disease.
ATCC increases focus on scientific reproducibility and leverages technological advances with new senior executive appointments
ATCC, the premier global biological materials resource and standards organization, is pleased to announce two important appointments to the senior leadership team. Barbie Bigelow has joined ATCC as Executive Vice President of Strategy and Technology and Dr. Maryellen de Mars also joins as the Senior Director for the Standards Resource Center. Both roles are new positions at ATCC.
AstraZeneca announced today that its global biologics research and development arm, MedImmune, has received fast track designation from the US Food and Drug Administration (FDA) for its investigational monoclonal antibody (mAb) MEDI3902 for the prevention of nosocomial pneumonia caused by Pseudomonas aeruginosa (P. aeruginosa).
Pseudomonas aeruginosa (P. aeruginosa) causes serious disease in hospitalised patients. The FDA’s Fast Track programme is a process designed to expedite the development and review of drugs to treat serious conditions and fill an unmet medical need.
There are two prevailing perceptions about innovation and start-ups: first, they are all tech driven, and second, they originate from just a few regions — chief among them, Silicon Valley. I’ve seen firsthand that innovation can happen anywhere, and that it is accelerating in places that typically don’t grab headlines. And I have met hundreds of entrepreneurs living in cities in “flyover country” that are building great companies and creating jobs in a wide range of industries.
A drug used to treat advanced breast cancer has had what appears to be unprecedented success in prolonging lives in a clinical trial, researchers reported on Sunday.
Patients who received the drug — Perjeta, from the Swiss drug maker Roche — had a median survival time nearly 16 months longer than those in the control group.
Medimmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca (LSE: AZN), has entered into a collaboration to establish a joint lab in Cambridge, UK, with Cancer Research Technology, the commercial arm of Cancer Research UK.
The new laboratory will be the first partnership of its kind of both organizations, and will focus on the discovery and development of biologic cancer treatments over an initial five-year period.
Officials from local and state government as well as business and education attended a virtual ribbon cutting on Wednesday to celebrate the opening of the new $71 million Center for Communications and Information Technology at Maryland’s Frostburg State University.
“This is one of the most technologically advanced learning centers in the United States. Every inch of this building fosters learning,” said Jonathan Gibralter, FSU president.
The Baltimore Business Journal has selected honorees for its first-ever Health Care Innovators awards.
These winners created new health care products and strategies that have made health care more accessible, efficient and effective. They will be featured in the Nov. 7 issue of the Baltimore Business Journal and will be recognized at a breakfast at the Hotel at Arundel Preserve on Nov. 7. Farzad Mostashari, the former national coordinator for health IT for the federal health department, will be the keynote speaker at the event.
The FLC is pleased to offer its latest on-demand, and FREE, e-learning course, “Introduction to CRADAs”! If you’re new to tech transfer and need to know more about one of its most important mechanisms, this introductory-level e-course is perfect for you.
Available free of charge and at your convenience, the course covers essential CRADA knowledge:
GSK and venture capitalists Avalon have launched two early-stage R&D biotechs in San Diego, California.
Silarus Therapeutics and Thyritope Biosciences will each receive $10m (€8m) in a Series A financing round to investigate the hormone behind anaemia, and anautoimmune disease.
With so much venture capital being foisted onto the digital health space, it’s beginning to beg the question: how long will this last, can it sustain itself, and what’s an entrepreneur to do? And, what are the implications for emerging companies versus traditional healthcare companies and systems?
Those were just a few of the burning questions discussed at Health 2.0‘s Pre, Post, M&A IPO panel held in Santa Clara.
American University’s Kogod School of Business on Friday plans to show off its new on-campus start-up incubator, the latest in a string of co-working spaces to pop up in and around the nation’s capital.
The incubator, one of the key components of the school’s recently announced Sustainable Entrepreneurship and Innovation Initiative, aims to provide current students and recent graduates with work space and pair them with a business mentor to help get their fledgling ventures off the ground. In addition, each business team will received a $1,500 grant to cover some initial start-up costs, such as the legal work necessary to incorporate a company.
New Enterprise Associates, a venture capital firm that has backed the likes of Groupon and Salesforce, is now investing in a biotechnology company developing a treatment for cancer.
The venture firm, which has a significant health care business, has led a $104 million financing round in Adaptimmune Limited, the company announced on Wednesday evening. The round, at the Series A stage, is believed to be among the largest for a biotechnology company at this early point of its development.
The Atlantic Vaccines and Immunotherapeutics Summit is a first-of-its-kind event to showcase Maryland’s global leadership as an epicenter of vaccine innovation, development and commercialization. The Tech Council of Maryland is presenting this conference to bring together the industry’s foremost researchers and business leaders for the purpose of educating, sharing, and collaborating on important issues affecting the new generation of vaccines.
The Summit’s agenda will focus on a spectrum of topics including global R&D; government priorities and challenges; regulatory processes and policies; university and academic development; models for regional synergy; and vaccine market impact. We invite you to join us for this two-day event on May 7-8, 2015 at the Bethesda North Marriott in Bethesda, Maryland.
Winners of the second annual Baltimore Innovation Awards included a civic hacker and a youth outreach organization.
The awards, a centerpiece of Baltimore Innovation Week’s Innovation Celebration, held Friday outside Under Armour headquarters in Tide Point, were announced in a brief presentation by Christopher Wink, editorial director and cofounder of Technical.l
The success of Alibaba’s blockbuster initial public offering in the U.S. has catapulted founder Jack Ma into the limelight and given him the status of China’s richest man.
The making of Alibaba began in 1999 when e-commerce was unheard of in China. Recalling the days when he started the venture with 17 friends in his flat in the South-eastern Chinese city of Hangzhou, Ma once said: “I called myself a blind man riding on the back of blind tigers.” 15 years later, the firm is the dominant player in China’s e-commerce space. Between its two main online marketplaces Taobao and TMall, Alibaba accounts for nearly 80 percent of the mainland’s e-retail transactions.
Tanisha Robinson is on tech startup No. 4 or so, with two running simultaneously at the moment, and aiming to make the latest a billion-dollar business. Here’s her best test to find if someone has what it takes to become an entrepreneur:
“If I were to take your wallet and your phone and your keys, and say you have to survive on your wits for a week,” she said.
Being an entrepreneur can mean a demanding, unpredictable schedule; spreading oneself way too thin; and trying to pull off tremendous, seemingly impossible feats. This sometimes leads to burnout, and even if we don’t want to admit it, unhappiness. Matthew Toren penned a piece for Entrepreneur about habits of healthy, happy, and wise entrepreneurs. One of the best practices that leads to happiness? Setting and enforcing boundaries. Sounds obvious, but definitely easier said than done when you’re trying to please everyone from employees to spouses. Toren recommends:
In the 24 years since the founding of the Georgia Research Alliance, federally-funded research and development grants to Georgia’s universities has increased five-fold.
The state’s total share of federal research funding increased to nearly 3 percent, ranking 12th and one of only five of the top 16 states that is increasing its market share.
The Texas Medical Center has more square footage, more doctors and more hospitals than any other medical center in the country. However, that has not translated into product commercialization necessarily.
Its new accelerator may be the catalyst that changes that, experts say.
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
Tasly Pharmaceuticals, Inc., a global leader in pharmaceuticals, biologics, and nutraceuticals, held a ribbon-cutting ceremony on September 3, 2014, at Tasly’s corporate offices in Rockville, MD.
The ceremony marked the official launch of Tasly’s Rockville location as the North American headquarters of Tasly Holding Group, a twenty year old global technology company established in China.
More than 100 distinguished guests and dignitaries were in attendance, including the Chairman and the President of Tasly Holding Group, China’s Embassy Counselor, Maryland state officials, Maryland biotechnology and pharmaceutical executives, and high-level regional media representatives, among others.
This editor attended TEDMED 2014 in DC and had a chance to speak with some of the innovative start ups in the Hive, a showcase of new medical technologies.
BeneVir has developed an impressive immunotherapy for cancer that has the potential to become a lasting, durable cure to the disease. While other existing immunotherapy treatments exist, these solutions only help the immune system scour the body for known cancer cells afflicting a patient. These solutions fail to educate the immune system on how to predict, recognize, and kill cancer mutations that avoid the immune system and lead to a recurrence of the disease. BeneVir’s solution uses a natural human virus whose genes have been altered to allow the virus to target both the original cancer cells and their mutations. Prior to becoming a company, BeneVir’s founders originally developed their immunotherapy concept and licensed the solution to T-Vec, which was acquired by Amgen for $1B in 2011. This original concept recently completed a Phase 3 clinical trial showing a 16% durable cure for melanoma. With this success, BeneVir was formed to expand on the original innovation with what the founder calls version 2.0 plus. With deep technical knowledge, BeneVir is refining their original immunotherapy solution to become an even more potent cancer therapy.
OpGen, Inc., a whole-genome analysis company developing and commercializing a complete suite of break-through products and services based on its proprietary Whole Genome Mapping technology, announced today the appointment of Vadim Sapiro as chief information officer. In addition, the company announced the promotion and appointments of several key members of the executive committee. The organizational changes have been made to strengthen the management team and accelerate OpGen’s development and commercialization strategy. The company’s products enable rapid, accurate, high resolution whole genome analysis of microbes as well as more cost effective and accurate sequence assembly and finishing of human, animal, plant and microbial genomes.
The 2014 NIH Research Festival, the annual showcase of the NIH Intramural Research Program, will be held Sept. 22-24. This year’s theme is “The Era of the Brain.” The festival kicks off with an opening plenary session at 10 a.m. on Monday, Sept. 22 in Masur Auditorium, Bldg. 10. The plenary session will include remarks by NIH director Dr. Francis Collins, followed by the FARE awards ceremony and scientific talks by Drs. Antonello Bonci (NIDA) and Mark Hallett (NINDS).
Oculus CEO Brendan Iribe first began working with computers in the 1980s, just as personal computers were entering homes. “I always said that it was the most exciting, amazing time,” he says. “We had no idea that in some number of years, a personal computer would within two physical taps, revolutionize, say, the entire taxi service industry.”
He has since revised his definition of the most exciting time to be in computer science to “now.”
Wednesday, October 15, 2014, 08:30am – 11:45am Johns Hopkins University – Montgomery County
This event is to gather interested small businesses seeking assistance from the Small Business Innovation Research grants program from the National Institutes of Health. This is a free event brought to you by BioHealth Innovation. Hear from the SBIR managers on current Institute funding priorities. Meet one-on-one with program managers regarding your current project. Learn of SBIR assistance provided by BioHealth Innovation.
Contact Ethan Byler at ebyler@biohealthinnovation.org if you are interested in scheduling one-on-one meetings.
The 2014 Innovation2Commercialization Conference will be held on October 23rd at the Universities at Shady Grove in Rockville. This is our third year and we would like to ask you participate again to support and encourage the innovators, scientists, technologists and entrepreneurs in our area.
The conference will be held from 7:30am-3:30pm, with three panels: Innovation, Commercialization and Financing, and a special Keynote Speaker – Rachel King, CEO, GlycoMimetics. The program will spotlight serial entrepreneurs and successful tech transfer to product from the Naval Research Laboratory and The Johns Hopkins University – including a full panel discussion on the successful development to exit for Amplimmune.
As Partners in the past, we hope you found participation in the I2C Conference productive and plan to join us again this year.
AstraZeneca and Eli Lilly and Company have reached an agreement for the development and commercialization of the oral beta secretes cleaving enzyme (BACE) inhibitor, AZD3293, which might become a viable treatment for Alzheimer’s disease. The oral therapy is expected to prevent the formation of amyloid plaque, which is comprised of peptides called amyloid beta, and slow the disease progression.
The agreement established stipulates that AstraZeneca will pay up to $500 million in development and regulatory milestone payments. Lilly announced that it is planning on receiving the first milestone payment of $50 million in the first half of 2015. Future costs will be equally shared by both companies, including net global revenues post-launch.
Tuesday, October 7, 2014 from 6:00 PM to 8:00 PM (EDT)
Rockville, Maryland
In February 2013, The Sunshine Act was included as the Transparency Reports and Reporting of Physician Ownership or Investment Interests section of the Patient Protection and Affordable Care Act (ACA). The Sunshine Act requires manufacturers of drugs, medical devices, and biologicals that participate in U.S. federal healthcare programs to report certain payments and items of value (typically $10 or more and totaling $100 annually or greater) given to physicians and teaching hospitals. Failure to stay in compliance may result in fines ranging from $10,000 to $1,000,000 annually. Whether you are a practicing physician or your startup has a medical device, drug, or related product, you are impacted by the ACA’s Physician Payments Sunshine Act. In July, CMS proposed removing the reporting exemption for any payments or transfers of value made to physicians who participate in accredited CME programs. We’ll talk with experts in compliance and policy who will share their experiences in implementing these new policies and how you can understand the implications of the law, dispute inaccuracies, and stay in compliance!
The Johns Hopkins University in Baltimore and other research institutions closer to Greater Washington have received hundreds of thousands of dollars from the ALS Association in the past few years.
Early indications are that some are likely to see even more in the future as contributions to the viral “Ice Bucket Challenge” have surpassed $113 million.
Accepting Applications for InvestMaryland Challenge!
Could $100,000 help jumpstart your startup? Well, Maryland’s national business competition is back for the third year!
Since 2013, InvestMaryland Challenge has awarded nearly $1.5M in prizes to innovative startup companies. Prizes have included cash grants, incubator space, marketing and legal services, and opportunities to pitch investors.
Start an application today and your business could be on its way to accepting the $100,000 Grand Prize!
An entrepreneurial and innovative spirit filled the conference room Tuesday, Sept. 16, at the Talbot County Free Library in Easton.
As part of Innovation Week, the third annual Startup Maryland Pitch Bus tour made a stop at the library. Business representatives from the additive manufacturing industry, commonly known as 3-D printing, also had 3-D printers and products on display.
The pitch bus offered an opportunity for area entrepreneurs to make a video for public viewing on YouTube to compete for venture investment.
A competition by Washington, D.C.-based incubator 1776 in a global search for the finest startup has set down the groundwork for its annual Challenge Cup in search of technology and healthcare startups. It is working with incubators in 16 cities around the world to identify early-stage companies across education, energy health and environment in a new twist to the competition called ChallengeX.
It begins in Washington, D.C. on October 21 and in Chicago on October 28, according to a company statement. In addition to those cities, it is working with incubators in Sydney, New York City, Tel Aviv, Amman, Santiago, Nairobi, Mumbai, Austin, Toronto, Boston, Berlin, Dublin, San Francisco and China. Each city will have four winners in each of the categories and advance to a week long festival in May when entrepreneurs for these companies have a chance to pitch investors, receive mentoring and meet policymakers. The intention of the Challenge Cup is to search for meaningful technology that’s also scalable.
More than 300 entrepreneurs are expected to vie for between 150 and 175 spots on the Startup Maryland bus to film a pitch video of their idea.
Now in its third year, the Startup Maryland’s Pitch Across Maryland tour will make 27 stops where entrepreneurs can film a short pitch video about their business. A panel of judges selects eight finalists, of which a winner and runner up are entered into a finalist round of the state’s InvestMaryland Challenge business competition.
DC I-Corps, a new, NSF-supported program designed to foster, grow and nurture an innovation ecosystem in the Mid-Atlantic Region, is now accepting applications for its fall cohort, beginning on October 9. Applications will be accepted on a rolling basis up until that date. Apply here.
Open to research teams and technology entrepreneurs from universities, federal laboratories, agencies and the general community, the free program guides researchers in exploring the commercial potential of their inventions.
The ever-shrinking number of biotech venture capital firms was a common refrain during the 2008-2012 period; it’s true that a large number of firms went under, closed their doors for new investments, or moved into zombie status. I wrote on the subject back in July 2012 (here). The biotech investing environment then, with a relatively bleak IPO landscape and venture funding off some 40% from the prior year, was very different from the past two years with an “open” IPO window and steady pace of venture funding.
On September 16, the American Academy of Arts and Sciences released a report entitled Restoring the Foundation: The Vital Role of Research in Preserving the American Dream. The report addresses the link between scientific research and advancing innovation and prosperity, and contains recommendations for strengthening its role to address challenges in the 21st Century. The recommendations fall under three overarching objectives: securing America’s leadership in science and engineering research; ensuring that the American people receive the maximum benefit from federal investments in research; and regaining America’s standing as an innovation leader by establishing a more robust national government-university-industry research partnership.
As of 2014, Deloitte is the largest professional services firm in the world by revenue. What began in the 19th century as stand-alone accounting offices has merged and evolved into a partnership that encompasses 200,000 employees in more than 150 countries around the globe.
But size alone doesn’t make a company great, of course. Things like satisfying clients, increasing opportunities for personnel, and performing a vital function for society make a company great. When employees, customers, investors, and the community benefit from a company’s services, that’s what makes it stand out from the rest.
Washington state’s Providence Health & Services today said it is launching a $150 million venture capital fund to help spur innovation across the healthcare system that lowers costs and leads to better outcomes.
Coincidentally, it’s the second VC fund announced in as many days on the West Coast, following yesterday’s announcement from the University of California.
FasterCures, part of the Milken Institute dedicated to improving drug development by encouraging greater patient involvement is searching for digital health entrepreneurs to pitch at its upcoming conference, Partnering for Cures. The group is looking for collaboration opportunities between biotech and digital health, partly to find more effective ways to improve clinical trial recruitment.
Entrepreneurs for Cures will spotlight entrepreneurs who are developing digital and mobile health technology that boost patient participation in biomedical research and development and those looking for partnerships with patient communities to demonstrate their product’s capabilities. It’s particularly interested in companies pursuing solutions geared to chronic conditions, acute and infectious diseases, mental illness, genetic conditions.
Since its passage more than two years ago, the Jumpstart Our Business Startups (JOBS) Act, which was designed to decrease regulatory burdens for raising capital, has spurred more than 110 IPOs among biotechnology companies alone. These are companies working to find cures for cancer, cardiovascular disease, blood disorders, and infectious diseases, among other conditions. The Securities and Exchange Commission (SEC) is now in the process of finalizing another important provision of the law that could further encourage biotech capital formation and investment.
Dutch venture capitalist Aglaia has announced the launch of Aglaia Oncology Fund II. Investors contribute a total of $65 million to the fund, whose target size is $80 to $100 million. Like its predecessor Aglaia Oncology Fund I, the fund is backed by high-net-worth families. The group of investors has now been expanded to include several institutional investors, including the European Investment Fund (EIF), which has made a substantial commitment. Aglaia is also one of the funds selected under the Dutch Venture Initiative, an investment fund recently launched by the Netherlands Ministry of Economic Affairs.
Through the new fund, Aglaia will be investing in an estimated ten to fifteen biotechnology start-ups which are in the process of developing groundbreaking technologies aimed at preventing and curing cancer.
The intersection of health and big data is getting more crowded. San Mateo, Calif.-based Lumiata is the latest company to get venture backing for technology that crunches data with the aim of improving medical care, Yuliya Chernova reports for Dow Jones VentureWire.
The company has already run an analysis of some 100,000 BlueCross BlueShield patients that found about 10,000 people who were very likely to have congestive heart failure, even though they were undiagnosed. Now the insurance provider, which is also an investor in the company, is alerting doctors who have those patients about this potential missed diagnosis.
AS a former physician, I shivered a bit when I heard Dr. Vivek Wadhwa say he would rather have an artificial-intelligence doctor than a human one. “I would trust an A.I. over a doctor any day,” he proclaimed at a recent health innovation conference in San Francisco, noting that artificial intelligence provided “perfect knowledge.” When asked to vote, probably a third of those in attendance agreed.
But it made sense: Dr. Wadhwa is a professor, entrepreneur and technology visionary. What’s more, the conference took place in San Francisco, where faith in the power of technology and data to solve problems holds unshakable sway.
Recognizing the continuing evolution of New Jersey’s life sciences industry, BioNJ today released a comprehensive report that documents the ongoing growth of the biotechnology sector in the State and combines and assesses the contributions of the entirety of the life sciences sector to New Jersey’s economy, including employment and economic impact.
BioNJ conducted the study in partnership with EY (formerly known as Ernst & Young) the Edward J. Bloustein School of Planning and Public Policy (Bloustein School) and the New Jersey Department of Labor and Workforce Development’s (LWD) Office of Research and Information. To access the study go to: http://www.bionj.org/wp- content/uploads/2014/09/Industry-Study-9-19-14-Final-Final.pdf.
Earlier this year, both Apple and Google presented competing visions for how we’ll use apps and wearables to gather data about our bodies and share it via our phones. Apple called its software HealthKit, while Google presented Google Fit.
If things had gone according to plan on Wednesday, Apple would be enjoying a head start over Google, with HealthKit released along with iOS 8, its new mobile software for iPhones and iPads. (Google Fit is still unreleased beyond a “developer preview.”)
Some of the trends in American health care are obvious: Managing costs in the age of Obamacare, patients using online information to take charge of their own health and wellness, and finding ways to deliver care in settings other than hospitals and clinics.
Those trends become specific, sometimes knotty, challenges for people engaged in building the tools needed to effectively, efficiently and safely deliver health care.
Envisioning, designing and manufacturing medical devices – which range from robots to sensors, and from surgical instruments to software that allows devices to communicate with one another – was the topic of a conference Thursday and Friday in Chicago.
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
BioHealth Innovation, Inc. (BHI) announced today that Roche Pharma Research and Early Development (pRED) and BHI have entered into an agreement to advance healthcare technologies coming from academic institutions, federal laboratories and startups based in Central Maryland. Under the terms of the agreement, BHI will identify health technologies that Roche will evaluate for potential research, development and commercialization opportunities. Priority areas of interest will include oncology, neuroscience, ophthalmology, rare diseases, immunological and infectious diseases. Financial terms for the agreement were not disclosed.
The agreement was initiated through Roche pRED Academic Relations and Collaboration (ARC) group, which is led globally by Juan Carlos Lopez. “Sourcing of technologies from academia, federal labs and early-stage startups can be a challenging and lengthy process,” said Lopez. “As we seek to expand our capabilities to source and screen technologies aligned with our strategic interests, BHI is an ideal partner to support identification of external opportunities in a broad, systematic fashion.”
Tasly Pharmaceuticals, Inc (Tasly) and BioHealth Innovation (BHI) co-organized the first Tasly Meeting of CEOs on Tuesday, September 2, 2014 at the Tasly facility in Rockville. Attendees included more than 25 CEOs and company representatives from local Maryland-based BioTech and BioPharma companies. This was the first public event conducted through Tasly and BHI’s newly initiated partnership.
Tasly is an innovation-based, high-tech healthcare and pharmaceutical enterprise and world-leader in the research and product development (R&D) of Chinese herbal medicine – the leader in the natural way to modernize medicine, with a North American headquarters in Rockville, Maryland, . Tasly and BHI have a formalized partnership which aims to co- organize and coordinate joint BioHealth associated events to promote professional networking, business growth, and technology and product commercialization.
Wednesday, October 15, 2014, 08:30am – 11:45am Johns Hopkins University – Montgomery County
This event is to gather interested small businesses seeking assistance from the Small Business Innovation Research grants program from the National Institutes of Health. This is a free event brought to you by BioHealth Innovation. Hear from the SBIR managers on current Institute funding priorities. Meet one-on-one with program managers regarding your current project. Learn of SBIR assistance provided by BioHealth Innovation.
Contact Ethan Byler at ebyler@biohealthinnovation.org if you are interested in scheduling one-on-one meetings.
Sebastian Seiguer had already founded emocha Mobile Health by the time his company began its four-month term in January 2014 as part of DreamIt Health Baltimore, an accelerator for developing health IT and health care startups that graduated its first class in May. But Seiguer’s venture, an online remote patient management platform for clinicians to monitor patients’ symptoms and recovery via smartphone, was a one-man operation, and he needed help.
“The rallying point was the accelerator,” says Seiguer, who launched emocha in fall 2013 by licensing technology from the Johns Hopkins University. “It allowed me to quickly recruit a strong team because there’s a lot of excitement generated by joining an accelerator and a solid program.”
Please plan to attend and also help spread the word about some exciting technology transfer programs planned for the NIH Research Festival next week:
Monday, September 22nd from 12-2pm
“Careers for scientists in technology transfer & business development” Poster Session I Building 10 – FAES Academic Center Presenter: Steve Ferguson (NIH/OTT)
Monday, September 22nd from 12-2pm
“NIH and the Federal Laboratory Consortium for Technology Transfer” Poster Session I Building 10 – FAES Academic Center Presenters: Steve Ferguson (NIH/OTT) and Gary Jones (Federal Laboratory Consortium)
Monday, September 22nd from 2-4pm
“Commercial Development of my Research: Still More Personal Stories from former NIH Intramural Scientists” Concurrent Symposium Session I Building 10 – FAES Academic Center – Classroom 3
Co-chairs: Steve Ferguson (NIH/OTT) and Todd Chappell (BioHealth Innovation)
The CEO and co-founder of Oculus VR is giving the University of Maryland $31 million – the largest gift in university history – to construct a computer science building.
University officials said late Thursday that alumnus Brendan Iribe’s gift will help build the Brendan Iribe Center for Computer Science and Innovation. Most of the gift will go toward the building, which will be designed for work in virtual reality, augmented reality, computer vision and robotics, and $1 million will establish the Brendan Iribe Scholarship in Computer Science.
Harpoon Medical, Inc., a medical device company focused on the development and commercialization of a minimally invasive, beating heart mitral valve repair technology, announced today that the company has successfully raised $3.2M of new capital and expects to complete the round over the coming weeks. The Series A financing was led by Epidarex Capital in order to advance Harpoon’s innovative technology into the clinic and expand the company’s research and development efforts.
“We are very pleased with the results of our Series A financing because it gives Harpoon Medical the resources necessary to advance the technology from an innovative concept into the clinic,” said, Bill Niland, CEO of Harpoon Medical, Inc. and serial healthcare entrepreneur. The round was increased to accommodate strong demand from investors that include the Maryland Venture Fund, the Abell Foundation, medical device executives, doctors and successful business executives in the Maryland area. “When you have the opportunity to put together a high caliber syndicate of investors who can help you with more than just capital you find a way to accommodate the demand.”
Brendan Iribe dropped out of the University of Maryland here, but before he did he amassed 227 parking tickets. And he managed to meet two business partners who would help him build the virtual-reality company Oculus VR, which Facebook bought this year for about $2-billion.
One of those parking tickets remains unpaid, but the university is likely to forgive it after Friday, when he gave $31-million to erect a computer-science building. That makes Mr. Iribe, who is 35 years old, the institution’s most generous donor ever.
The Johns Hopkins University has entered into a partnership agreement with Google’s Advanced Technology and Projects group aimed at speeding up the development of new technology and moving the resulting products toward the marketplace more quickly.
The agreement will enable ATAP to draw on the expertise of computer scientists and others at Johns Hopkins and approve funds for joint technology projects in as few as 30 days. That turnaround time is much shorter than the period typically required for obtaining grants from government agencies and private organizations.
As the Ebola death toll climbs above 2,000, a university researcher is working to develop a vaccine for the virus.
Alan L. Schmaljohn, a microbiology and immunology professor at University of Maryland, Baltimore, has successfully isolated one of the structural sections of the virus, which can be used as a platform for a working vaccine.
Pluristem Therapeutics, a company that develops placenta-based cell therapy products, announced that its licensing partner United Therapeutics is advancing the Phase I study of Pluristem’s PLacental eXpanded (PLX-PAD) cells in patients with pulmonary arterial hypertension (PAH).
PLacental eXpanded (PLX) cells are developed by Pluristem to serve as protein delivery platforms that release a mix of proteins for ischemia or inflammation. The treatment technology is also being used to investigate tendon-healing treatments in a preclinical model of tendon injury. The company presented results at the American Academy of Orthopedic Surgeons’ (AAOS) Annual Meeting last March in New Orleans.
In the fight against cancer, Johns Hopkins University is invoking a popular attitude these days: go big or go home.
The Johns Hopkins radiation oncology department has teamed up with Toshiba Group to establish the Toshiba Center for Big Data in Healthcare at the Science + Technology Park at the Hopkins campus in Baltimore.
A white powdered chemical compound emerged from two University of Maryland School of Medicine laboratories more than 10 years ago with a name destined for oblivion, but a future that now looks promising as a treatment for the most challenging cases of prostate cancer.
Today, VN/124-1 is a drug candidate with a name — galeterone — a pharmaceutical company founded on its potential and a record of strong preliminary results in clinical trials with human patients.
Startup Maryland announced support from TEDCO (www.tedco.md) as a full-tour sponsor of the Pitch Across Maryland 2014, the third annual state-wide tour and celebration of entrepreneurship and startup companies.
Starting on September 15 and running through October 3 the Pitch Across Maryland tour will again traverse the state all in the name of celebrating Maryland’s diverse communities of venture building.
“Maryland’s innovation economy is front-and-center in many of the most lucrative industry and innovation categories,” stated Michael Binko, founder of Startup Maryland. “From traditional ‘feds, eds and meds’ (government/education/healthcare/life sciences-bio), to cloud computing, cyber-security, creative/arts, clean energy/green, to autonomous systems, Maryland entrepreneurs are breeding innovation ventures that are disrupting a wide array of industry sectors and TEDCO has consistently been the recognized leader in early-stage resource commitments.”
Optum Labs has named the University of Maryland, Baltimore (UMB) as one of the latest partners to join its research collaborative. Led by Eleanor Perfetto, PhD, MS, professor in the Department of Pharmaceutical Health Services Research (PHSR) at the University of Maryland School of Pharmacy, this new partnership will enhance and augment UMB’s existing research and informatics resources with the data, tools, expertise, and infrastructure available at Optum Labs to increase the scope and impact of Alzheimer’s disease and healthy aging research.
“This partnership with Optum Labs enhances UMB’s recognition as a leader in ‘big data’ research,” says Perfetto. “In addition to expanding research opportunities for faculty and students across the University, the partnership increases our competitiveness for grants and contracts from industry, government, and philanthropic organizations. We look forward to combining our expertise and resources with those at Optum Labs to pursue innovative projects that will improve health care delivery and patient outcomes for individuals with Alzheimer’s diseases and other aging-related issues.”
Some of the greatest health care innovations have taken decades to reach widespread adoption, adding to the ever-increasing cost of health care.
We are looking for solutions that have already been implemented at least once and have demonstrated effectiveness. This “scale-up” competition seeks to shorten the time frame for innovation dissemination.
Say you invent a medical device. A pacemaker. An improved hip implant. A microchip for the brain. Maybe you can change the world, but first you’ll have to get approved.
A new graduate certificate program in the bioengineering department teaches students the ins and outs of gaining Food and Drug Administration approval. This process is necessary to test the safety and efficiency of all medical inventions before they hit the market, but it can take years of expensive research — and disapproval is common, said William Bentley, the bioengineering department chairman.
When we go grocery shopping, most of us don’t buy a pallet of one product and survive on that for the rest of our lives. We get our food more regularly, so it’s fresher and more in tune with our tastes of the moment. So why wouldn’t education in the fast-changing STEM fields, look like that too?
That was how Andrew Coy, the executive director of the Digital Harbor Foundation, put it during an informal tech leaders roundtable discussion at City Hall Thursday morning.
Today, the University announces the receipt of its largest gift ever by a single donor. It will catapult our top-15 computer science program to even greater national and international pre-eminence. It will spark innovation and entrepreneurship across the campus and catalyze new economic development in the state.
The gift began after a tragedy and will end in a living memorial. It demonstrates the impact of friendship, teamwork, and family—qualities that ultimately benefit our students and faculty.
The innovation program designed to move academic findings and translational research into the commercial marketplace, known at Johns Hopkins University as FastForward, is expanding early next year, with a second facility scheduled to open in East Baltimore to provide lab and office space for startups. Some lab space will be available starting in September 2014.
The first accelerator, FastForward Homewood, at the historic Stieff Silver Building near Homewood campus, was opened by the Whiting School of Engineering in June 2013, and today it houses nine startups from across the university. The second incubator, FastForward East at the Rangos Building on North Wolfe Street, will be more closely tied to the Johns Hopkins School of Medicine, the Bloomberg School of Public Health, and the Johns Hopkins School of Nursing, while still allowing scientists and technical experts from a wide background to take advantage of the new facility.
Get answers now from experienced entrepreneurs and legal/business professionals on how to build a successful startup company. Receive free and impartial advice, brainstorm business strategies, investigate funding opportunities and learn about the vast resources available to entrepreneurs.
DATE: September 16, 2014
PLACE: Columbus Center, 701 East Pratt Street, Baltimore, Maryland 21202 USA
There were few surprises for local colleges and universities in the oft-quoted U.S. News and World Report annual rankings released Tuesday.
The Johns Hopkins University maintained its 12th-place position for national universities, falling between Dartmouth and Northwestern. Hopkins is focusing on its undergraduate experience, with a goal of making it among the top 10 in the nation by 2020.
nvestors in entrepreneurs have a special in-the-trenches wisdom gained through years of experience. This investor experience is now available to entrepreneurs and prospective early-stage investors through InvestorIQ.org, a free, online curriculum that provides knowledge essential to improving startup investment.
Investor IQ allows startup backers and founders to educate themselves on how investors decide whether to invest at all, where to invest, and how their money will be used and returned. A video series draws on the successes and failures of thousands of angel investors over the last 15 years, delving into five questions early-stage investors should ask themselves before they put money into an entrepreneurial venture.
It’s no surprise that social-media campaigns can raise awareness of an issue, but the ALS Ice Bucket Challenge may be unprecedented in its impact on a relatively rare disease. The campaign, in which participants must donate to an ALS cause or take videos of themselves being doused in ice, has gone viral since it began in late June. But it has also generated controversy, with some questioning the attention and flood of cash for a disease that affects a small number of people.
As of Friday, the ALS Association had received $53.3 million since July 29, compared with $2.2 million by that time last year. To put it in perspective, the National Institutes of Health’s yearly budget for ALS research is $40 million. Other ALS charities are also benefitting similarly from the campaign.
The Southern Maryland Innovation and Technology (SMIT) initiative has awarded Smartronix and Coherent Technical Services, two locally headquartered technology firms, Pro Memberships to CoFounders Lab.
CoFounders Lab, a OneVest Company, is an online partnering platform of more than 40,000 founders, advisers and interns available to help launch and grow businesses. A Pro Membership provides access to entrepreneurs nation-wide to help individuals connect with the right partner, investment or resource needed to take a business to the next level. SMIT will award 40 Pro Memberships to individuals and companies to encourage technical innovation and commercialization in St. Mary’s County.
Over the course of three days at the Mayo Clinic‘s annual Transform conference, featuring scores of healthcare’s top names, several themes stood out. Here’s what I gather were the main points.
1. Economic factors and barriers are just as important in determining health outcomes for the population as a whole. It stands to reason – people with fewer financial resources are often forced to choose between paying for a costly lab test or doctor visit or putting food on the table, among countless other instances and examples.
My last post, How Successful People Stay Calm, really struck a nerve (it’s already approaching 1.5 million reads here on LinkedIn). The trick is that managing your emotions is as much about what you won’t do as it is about what you will do.
TalentSmart has tested more than a million people and found that the upper echelons of top performance are filled with people who are high in emotional intelligence (90% of top performers, to be exact). So, I went back to the data to uncover the kinds of things that emotionally intelligent people are careful to avoid in order to keep themselves calm, content, and in control. They consciously avoid these behaviors because they are tempting and easy to fall into if one isn’t careful.
There has been a long-running debate in the pharmaceutical industry about the value of being first to market. Companies spend considerable resources seeking to increase the odds of beating their competitors to market and often fret about the commercial disadvantage of being late. In the high-stakes race to market for a novel drug class, companies firmly believe that every month of lead time ahead of a competitor is significant.
It’s not quite that simple. Our analysis of pharma launches confirms a weak first-to-market advantage on average, but with significant nuances dependent on market context. In many instances, the first-mover advantage actually vanishes, particularly when the lead time is short or when the first mover is a small company. This article seeks to identify those situations where first-to-market advantage is strong and those where it does not hold.
This is the first in an exciting series of programs designed to keep you current on issues affecting you as a leader of your organization, and provides an opportunity to connect with your colleagues.
On October 7, Gary will discuss the role of disruptive technology in today’s market and how to create an adaptive, decisive, mission-oriented corporate environment that can help you drive your company forward. In addition to leading one of the largest associations of technology companies, Mr. Shapiro is at the helm of the International CES (Consumer Electronics Show), the world’s largest annual innovation event. It unites more than 150,000 retail buyers, distributors, manufacturers, market analysts, importers, exporters, and press from 150 countries.
Join us as Gary shares his passion for innovation and explains what it is like to be at the forefront of a multi-billion dollar industry and what is coming next. I look forward to seeing you at this terrific event. Click here to register now!
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
Wednesday, November 19, 2014, 05:00am – 07:00pm
The MCCC Business Awards Dinner Committee and Chair of the Board Lisa Cines, CPA of Dixon Hughes Goodman LLP invite you to join in the celebration of those who make our economy and community thrive. This annual sold-out event attracts 700+ guests including award winners, sponsors, business leaders, elected and government officials and the media. Join us for a great evening of Meaningful Connections, Commerce and Celebration.
Americans include two health-related issues among the 10 most important problems facing the U.S., according to a recent Gallup survey. Healthcare in general ranked fourth on the list, with Ebola coming in at no. 8. But is Ebola really among the biggest health problems for Americans? Not when we look at the chances of actually being infected.
Summary of Position:
Dutch biotech MIMETAS B.V. announces that it has raised 5.2 million dollar to fund its expansion as a global leader in organ-on-a-chip technology. Venture capital investors Zeeuws Investerings Fonds (ZIF) and Participatiemaatschapij Oost Nederland (PPM Oost) have joined forces with national and regional partners to fund development and sales of MIMETAS’ unique 3D disease- and tissue modelling technologies.
Wednesday, October 15, 2014, 08:30am – 11:45am
ROCKVILLE AND BALTIMORE, MARYLAND, September 30, 2014 – BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today that venture capitalist, Tania Fernandez, Ph.D., has joined the BHI team as a strategic advisor. Dr. Fernandez will be a member of the management team for a new BioHealth Gap Fund, which will provide up to $50 million in seed and early-stage equity investments to therapeutics, medical device, diagnostics, and health IT companies in Maryland. Additional BioHealth Gap Fund management team members include Richard Bendis, Ram Aiyar, Todd Chappell, and Ken Malone, who each bring domain knowledge and industry access to the fund.
On September 10, 2014, Tasly Pharmaceuticals, Inc. (Tasly) and BioHealth Innovation, Inc. (BHI) signed a Memorandum of Agreement (MOA) which aims to advance their business partnership. The MOA also lists specific near- and long-term collaboration activities between the two parties.
Rich Bendis was interviewed on 99.1 WNEW Newstime about partnering with Roche and describing what it is that BioHealth Innovation does for Maryland.
Tuesday, October 07, 2014, 08:00am – 10:00am
Tasly Pharmaceuticals, Inc., a global leader in pharmaceuticals, biologics, and nutraceuticals, held a ribbon-cutting ceremony on September 3, 2014, at Tasly’s corporate offices in Rockville, MD.
The 2014 NIH Research Festival, the annual showcase of the NIH Intramural Research Program, will be held Sept. 22-24. This year’s theme is “The Era of the Brain.” The festival kicks off with an opening plenary session at 10 a.m. on Monday, Sept. 22 in Masur Auditorium, Bldg. 10. The plenary session will include remarks by NIH director Dr. Francis Collins, followed by the FARE awards ceremony and scientific talks by Drs. Antonello Bonci (NIDA) and Mark Hallett (NINDS).
